Crystal forms of hydroxamic acid ester compound and salt thereof, and preparation method

Abstract

The present invention relates to a non-solvated crystal, hydrate crystal, solvated crystal, eutectic crystal or salt-type crystal of a compound as represented by formula (I),

Description

CRYSTAL FORMS OF HYDROXAMIC ACID ESTER COMPOUND AND SALT THEREOF, AND PREPARATION METHODTECHNICAL FIELDThe present invention belongs to the field of medicinal chemistry and particularly relates to crystalline forms of a hydroximate compound and salts thereof and a preparation method therefor. BACKGROUND6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide is a tyrosine kinase 2 (Tyk2) inhibitor, and its chemical structure is represented by structural formula (I).<!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f"><v:stroke joinstyle="miter" / ><v:formulas><v:f eqn="if lineDrawn pixelLineWidth 0" / ><v:f eqn="sum @0 1 0" / ><v:f eqn="sum 0 0 @1" / ><v:f eqn="prod @2 1 2" / ><v:f eqn="prod @3 21600 pixelWidth" / ><v:f eqn="prod @3 21600 pixelHeight" / ><v:f eqn="sum @0 0 1" / ><v:f eqn="prod @6 1 2" / ><v:f eqn="prod @7 21600 pixelWidth" / ><v:f eqn="sum @8 21600 0" / ><v:f eqn="prod @7 21600 pixelHeight" / ><v:f eqn="sum @10 21600 0" / >< / v:formulas><v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect" / ><o:lock v:ext="edit" aspectratio="t" / >< / v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:114.75pt; height:99.75pt' o:ole=""><v:imagedata src="tmpusyf2wzl_files / image001.emz" o:title="" / >< / v:shape><![endif]--><!--[if !vml]--><!--[endif]--><!--[if gte mso 9]><xml><o:OLEObject Type="Embed" ProgID="ChemDraw.Document.6.0" ShapeID="_x0000_i1025" DrawAspect="Content" ObjectID="_1800177690">< / o:OLEObject>< / xml><![endif]--> (I)PCT Patent Application No. PCT / CN2021 / 134929 contains pharmacological activity data of the compound represented by formula (I). This compound has excellent selective inhibitory activity against Tyk2 and can be used for treating diseases associated with abnormal Tyk2 activity. Clinically, it is expected to provide better efficacy with fewer drug side effects.Currently, there is no publicly available information on the compound represented by formula (I), nor have its crystalline forms, salt forms, or eutectic crystal structures, as well as methods for preparing its solvated crystals, non-solvated crystals, salt forms, and eutectic crystals, been found.Those skilled in the art know that different crystalline forms of a drug have a significant influence on the drug’s stability, solubility, bioavailability, and efficacy. Therefore, researching to obtain related crystals of the compound of formula (I) has a significant influence on the subsequent development of drugs and is of great significance. Providing various crystalline forms, salt forms, or eutectic structures can meet more different clinical needs. Therefore, based on the excellent clinical application prospects of the compound represented by formula (I), it is necessary to conduct further research on microstructures, such as crystals, salt forms, and eutectic crystals, of the compound represented by formula (I), in hope of obtaining more microstructures of the compound represented by formula (I) helpful for clinical drug development. SUMMARYThe problem to be solved by the present invention: the present invention aims to provide crystalline forms, salt forms, and eutectic crystalline forms of the compound represented by formula (I).Solutions to the problem:To resolve the problem described above, the present invention provides the following technical solutions.In a first aspect of the present invention, provided is a non-solvated crystal of the compound represented by formula (I),<!--[if gte vml 1]><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:114.75pt;height:99.75pt' o:ole=""><v:imagedata src="tmpusyf2wzl_files / image001.emz" o:title="" / >< / v:shape><![endif]--><!--[if !vml]--><!--[endif]--><!--[if gte mso 9]><xml><o:OLEObject Type="Embed" ProgID="ChemDraw.Document.6.0" ShapeID="_x0000_i1026" DrawAspect="Content" ObjectID="_1800177691">< / o:OLEObject>< / xml><![endif]--> (I).In some specific embodiments, the non-solvated crystal of the compound represented by formula (I) is selected from a non-solvated crystal AH of the compound and a non-solvated crystal E of the compound.In some specific embodiments, an X-ray powder diffraction pattern of the non-solvated crystal AH of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.65o, 11.26o, 11.43o, 15.07o, 15.32o, 19.07o, 20.12o, and 20.78o.In some specific embodiments, the X-ray powder diffraction pattern of the non-solvated crystal AH of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.65o, 11.26o, 11.43o, 15.07o, 15.32o, 16.60o, 19.07o, 20.12o, 20.78o, and 23.02o.In some specific embodiments, the X-ray powder diffraction pattern of the non-solvated crystal AH of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.65o, 9.47o, 11.26o, 11.43o, 15.07o, 15.32o, 16.31o, 16.60o, 19.07o, 20.12o, 20.78o, 23.02o, and 25.77o.In some specific embodiments, the X-ray powder diffraction pattern of the non-solvated crystal AH of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.65o, 8.36o, 9.47o, 9.80o, 11.26o, 11.43o, 11.55o, 11.80o, 12.95o, 13.64o, 14.34o, 14.74o, 15.07o, 15.32o, 15.91o, 16.31o, 16.60o, 16.87o, 18.72o, 19.07o, 19.73o, 20.12o, 20.78o, 21.30o, 21.45o, 21.95o, 22.31o, 23.02o, 23.30o, 23.67o, 23.84o, 24.65o, 25.77o, 26.57o, 26.90o, 28.29o, 28.85o, and 29.54o.In some specific embodiments, the X-ray powder diffraction pattern of the non-solvated crystal AH of the compound represented by formula (I) is shown in FIG. 7.In some specific embodiments, a differential scanning calorimetry analysis curve of the non-solvated crystal AH of the compound represented by formula (I) shows an endothermic peak near 188 oC and an exothermic peak near 216.7 oC.In some specific embodiments, the differential scanning calorimetry analysis curve of the non-solvated crystal AH of the compound represented by formula (I) is shown in FIG. 9.In some specific embodiments, a thermogravimetric analysis curve of the non-solvated crystal AH of the compound represented by formula (I) shows that the crystalline form undergoes a weight loss of 2.1% in the process of being heated to 150 oC and may decompose when further heated to higher than 190 oC.In some specific embodiments, the thermogravimetric analysis curve of the non-solvated crystal AH of the compound represented by formula (I) is shown in FIG. 10.In one embodiment, an X-ray powder diffraction pattern of the non-solvated crystal E of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.19o, 9.59o, 14.46o, 18.15o, 20.41o, 23.44o, 23.67o, 24.01o, 24.34o, and 24.60o.In one embodiment, the X-ray powder diffraction pattern of the non-solvated crystal E of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.19o, 9.59o, 13.64o, 14.46o, 18.15o, 19.19o, 20.41o, 23.44o, 23.67o, 24.01o, 24.34o, and 24.60o.In one embodiment, the X-ray powder diffraction pattern of the non-solvated crystal E of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.19o, 8.93o, 9.59o, 12.72o, 13.64o, 14.46o, 18.15o, 19.19o, 19.96o, 20.41o, 23.44o, 23.67o, 24.01o, 24.34o, 24.60o, and 28.60o.In some specific embodiments, the X-ray powder diffraction pattern of the non-solvated crystal E of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.19o, 8.93o, 9.59o, 10.14o, 10.52o, 11.74o, 12.31o, 12.72o, 13.64o, 14.46o, 15.33o, 15.85o, 16.62o, 17.02o, 18.03o, 18.15o, 18.72o, 19.19o, 19.36o, 19.96o, 20.41o, 20.90o, 23.44o, 23.67o, 24.01o, 24.34o, 24.60o, 25.69o, 26.66o, 28.60o, 29.19o, and 32.08o.In one embodiment, the X-ray powder diffraction pattern of the non-solvated crystal E of the compound represented by formula (I) is shown in FIG. 11.In one embodiment, a differential scanning calorimetry analysis curve of the non-solvated crystal E of the compound represented by formula (I) shows an endothermic peak near 194.2 oC and an exothermic peak near 217.1 oC.In one embodiment, the differential scanning calorimetry analysis curve of the non-solvated crystal E of the compound represented by formula (I) is shown in FIG. 13.In one embodiment, a thermogravimetric analysis curve of the non-solvated crystal E of the compound represented by formula (I) shows that the crystalline form undergoes a weight loss of 0.0% in the process of being heated to 150 oC and may decompose when further heated to higher than 190 oC.In one embodiment, the thermogravimetric analysis curve of the non-solvated crystal E of the compound represented by formula (I) is shown in FIG. 14.In one embodiment, the crystalline form of the non-solvated crystal E of the compound represented by formula (I) is a triclinic system with the following unit cell parameter values: a = 9.63590(19) Å; b = 10.6920(3) Å; c = 12.4689(2) Å; α = 76.404(2)o; β = 86.6962(16)o; γ = 70.126(2)o; space group: P-1; molecules in each unit cell (Z): 2; unit cell volume: 1173.91 Å3; and calculated density: 1.376 g / cm3.In a second aspect of the present invention, provided is a hydrate crystal of the compound represented by formula (I),<!--[if gte vml 1]><v:shape id="_x0000_i1027" type="#_x0000_t75" style='width:114.75pt;height:99.75pt' o:ole=""><v:imagedata src="tmpusyf2wzl_files / image001.emz" o:title="" / >< / v:shape><![endif]--><!--[if !vml]--><!--[endif]--><!--[if gte mso 9]><xml><o:OLEObject Type="Embed" ProgID="ChemDraw.Document.6.0" ShapeID="_x0000_i1027" DrawAspect="Content" ObjectID="_1800177692">< / o:OLEObject>< / xml><![endif]--> (I).In some specific embodiments, the hydrate crystal of the compound represented by formula (I) is selected from a hydrate crystal AA of the compound, a hydrate crystal T of the compound, a hydrate crystal V of the compound, and a hydrate crystal L of the compound.In some specific embodiments, an X-ray powder diffraction pattern of the hydrate crystal AA of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.85o, 10.35o, 12.74o, 14.95o, 17.94o, 18.05o, 19.01o, 20.90o, and 27.26o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal AA of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.85o, 8.92o, 10.35o, 11.18o, 12.74o, 14.95o, 17.94o, 18.05o, 19.01o, 20.90o, 24.39o, and 27.26o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal AA of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.85o, 8.62o, 8.92o, 10.35o, 11.18o, 12.74o, 14.95o, 16.71o, 17.94o, 18.05o, 19.01o, 19.99o, 20.90o, 21.57o, 24.39o, and 27.26o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal AA of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.85o, 8.62o, 8.92o, 10.35o, 10.80o, 11.18o, 12.74o, 14.95o, 15.64o, 16.14o, 16.71o, 17.18o, 17.63o, 17.94o, 18.05o, 18.73o, 19.01o, 19.53o, 19.99o, 20.63o, 20.90o, 21.57o, 22.25o, 22.54o, 22.81o, 23.18o, 23.79o, 24.39o, 24.90o, 25.16o, 25.86o, 26.08o, 27.26o, 27.50o, 27.93o, 28.16o, 28.32o, 29.73o, 31.97o, and 34.26o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal AA of the compound represented by formula (I) is shown in FIG. 3.In some specific embodiments, an X-ray powder diffraction pattern of the hydrate crystal T of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.31o, 6.09o, 6.82o, 11.05o, 18.49o, 19.74o, 24.32o, and 26.78o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal T of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.31o, 6.09o, 6.82o, 11.05o, 13.03o, 16.41o, 18.49o, 19.74o, 22.26o, 24.32o, and 26.78o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal T of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.31o, 6.09o, 6.82o, 8.65, 11.05o, 13.03o, 13.56o, 16.41o, 17.94o, 18.49o, 19.74o, 22.26o, 24.32o, and 26.78o.In one embodiment, the X-ray powder diffraction pattern of the hydrate crystal T of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.31o, 6.09o, 6.53o, 6.82o, 8.65o, 11.05o, 12.27o, 13.03o, 13.56o, 13.74o, 15.46o, 15.64o, 16.41o, 17.52o, 17.94o, 18.49o, 19.60o, 19.74o, 21.86o, 22.26o, 23.01o, 24.32o, 24.49o, 24.73o, 26.78o, 27.09o, 27.83o, 31.20o, and 33.11o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal T of the compound represented by formula (I) is shown in FIG. 20.In some specific embodiments, an X-ray powder diffraction pattern of the hydrate crystal V of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.34o, 7.48o, 7.95o, 10.27o, 12.97o, 17.90o, 20.71o, and 23.98o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal V of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.34o, 7.48o, 7.95o, 9.72o, 10.27o, 12.97o, 17.90o, 20.71o, and 23.98o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal V of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.34o, 7.48o, 7.95o, 9.72o, 10.27o, 12.97o, 14.34o, 17.90o, 18.19o, 20.71o, and 23.98o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal V of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.34o, 7.48o, 7.95o, 9.72o, 10.27o, 12.97o, 14.34o, 15.72o, 16.94o, 17.90o, 18.19o, 19.39o, 20.28o, 20.71o, 21.09o, 22.50o, 23.04o, and 23.98o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal V of the compound of formula (I) is shown in FIG. 22.In some specific embodiments, an X-ray powder diffraction pattern of the hydrate crystal L of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.69o, 8.02o, 9.93o, 14.23o, 16.13o, 16.29o, 18.13o, 19.18o, and 24.32o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal L of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.69o, 8.02o, 9.93o, 12.87o, 14.23o, 16.13o, 16.29o, 18.13o, 19.18o, 21.07o, 23.38o, and 24.32o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal L of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.69o, 7.07o, 8.02o, 9.93o, 12.87o, 14.23o, 16.13o, 16.29o, 17.47o, 18.13o, 19.18o, 21.07o, 23.38o, 24.32o, and 28.21o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal L of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.32o, 6.69o, 7.07o, 8.02o, 9.93o, 12.87o, 14.23o, 15.16o, 15.57o, 16.13o, 16.29o, 16.50o, 16.87o, 17.47o, 18.13o, 19.18o, 19.43o, 20.02o, 21.07o, 21.55o, 21.93o, 22.26o, 23.38o, 23.96o, 24.32o, 24.99o, 25.43o, 25.75o, 26.98o, 27.86o, 28.21o, 29.51o, 29.94o, 31.27o, and 33.20o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal L of the compound of formula (I) is shown in FIG. 26.In a third aspect of the present invention, provided is a solvated crystal of the compound represented by formula (I), and the solvent is selected from methanol, formic acid, and ethanol, <!--[if gte vml 1]><v:shape id="_x0000_i1028" type="#_x0000_t75" style='width:114.75pt;height:99.75pt' o:ole=""><v:imagedata src="tmpusyf2wzl_files / image001.emz" o:title="" / >< / v:shape><![endif]--><!--[if !vml]--><!--[endif]--><!--[if gte mso 9]><xml><o:OLEObject Type="Embed" ProgID="ChemDraw.Document.6.0" ShapeID="_x0000_i1028" DrawAspect="Content" ObjectID="_1800177693">< / o:OLEObject>< / xml><![endif]--> (I);wherein the ratio of the compound represented by formula (I) to the solvent is 1:0.3-1.In some specific embodiments, the solvated crystal of the compound represented by formula (I) is a methanol solvated crystal, and the ratio of the compound represented by formula (I) to methanol is 1:0.4-1.In some specific embodiments, the methanol solvated crystal of the compound represented by formula (I) is a methanol solvated crystal A.In some specific embodiments, in the methanol solvate crystal A of the compound represented by formula (I), the ratio of the compound represented by formula (I) to methanol is 1:1.In some specific embodiments, an X-ray powder diffraction pattern of the methanol solvate crystal A of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.56o, 9.16o, 9.34o, 12.91o, 13.78o, 14.66o, 15.25o, 18.52o, and 23.12o.In some specific embodiments, the X-ray powder diffraction pattern of the methanol solvate crystal A of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.56o, 9.16o, 9.34o, 12.91o, 13.78o, 14.66o, 15.25o, 16.52o, 18.52o, 20.58o, 23.12o, 24.02o, and 27.83o.In some specific embodiments, the X-ray powder diffraction pattern of the methanol solvated crystal A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.56o, 9.16o, 9.34o, 11.36o, 12.91o, 13.78o, 14.66o, 15.25o, 16.52o, 17.82o, 18.52o, 19.48o, 19.62o, 20.58o, 22.47o, 22.93o, 23.12o, 24.02o, 24.90o, 27.09o, 27.83o, 32.61o, and 37.44o.In some specific embodiments, the X-ray powder diffraction pattern of the methanol solvate crystal A of the compound represented by formula (I) is shown in FIG. 1.In some specific embodiments, the methanol solvated crystal of the compound represented by formula (I) is a methanol solvated crystal AE.In some specific embodiments, in the methanol solvate crystal AE of the compound represented by formula (I), the ratio of the compound represented by formula (I) to methanol is 1:0.4.In one embodiment, an X-ray powder diffraction pattern of the methanol solvate crystal AE of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 9.08o, 9.63o, 13.11o, 13.70o, 14.80o, 15.29o, 17.88o, 18.78o, 22.94o, and 23.46o.In one embodiment, the X-ray powder diffraction pattern of the methanol solvate crystal AE of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 9.08o, 9.63o, 13.11o, 13.70o, 14.80o, 15.29o, 16.68o, 17.88o, 18.78o, 20.16o, 22.94o, 23.46o, and 25.32o.In some specific embodiments, the X-ray powder diffraction pattern of the methanol solvated crystal AE of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.51o, 9.08o, 9.63o, 11.60o, 13.11o, 13.70o, 14.80o, 15.29o, 15.99o, 16.68o, 17.88o, 18.78o, 20.16o, 22.94o, 23.46o, and 25.32o.In one embodiment, the X-ray powder diffraction pattern of the methanol solvate crystal AE of the compound represented by formula (I) is shown in FIG. 5.In some specific embodiments, the solvated crystal of the compound represented by formula (I) is a formic acid solvated crystal, wherein the ratio of the compound represented by formula (I) to formic acid is 1:1.In some specific embodiments, the formic acid solvated crystal of the compound represented by formula (I) is selected from a formic acid solvated crystal F, a formic acid solvated crystal O, and a formic acid solvated crystal AF.In some specific embodiments, an X-ray powder diffraction pattern of the formic acid solvated crystal F of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.96o, 5.30o, 7.25o, 8.44o, 12.14o, 15.04o, 15.83o, 19.47o, and 20.11o.In some specific embodiments, the X-ray powder diffraction pattern of the formic acid solvated crystal F of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.96o, 5.30o, 7.25o, 8.44o, 9.93o, 12.14o, 12.91o, 14.62o, 15.04o, 15.83o, 19.47o, and 20.11o.In some specific embodiments, the X-ray powder diffraction pattern of the formic acid solvated crystal F of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): about 4.96o, 5.30o, 7.25o, 8.44o, 9.93o, 10.71o, 12.14o, 12.91o, 14.62o, 15.04o, 15.83o, 17.08o, 18.52o, 19.47o, 20.11o, 22.07o, 23.14o, 24.48o, and 25.64o.In some specific embodiments, the X-ray powder diffraction pattern of the formic acid solvated crystal F of the compound represented by formula (I) is shown in FIG. 16.In some specific embodiments, an X-ray powder diffraction pattern of the formic acid solvated crystal O has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.30o, 10.68o, 11.72o, 15.25o, 16.09o, 17.99o, 20.50o, 22.30o, 25.78o, and 26.57o.In some specific embodiments, the X-ray powder diffraction pattern of the formic acid solvated crystal O of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.30o, 10.54o, 10.68o, 11.72o, 13.73o, 15.25o, 16.09o, 16.96o, 17.99o, 20.50o, 21.00o, 22.30o, 25.78o, 26.57o, and 28.89o.In some specific embodiments, the X-ray powder diffraction pattern of the formic acid solvated crystal O of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.30o, 10.54o, 10.68o, 10.93o, 11.72o, 11.93o, 12.39o, 13.31o, 13.73o, 14.04o, 15.25o, 16.09o, 16.96o, 17.99o, 18.26o, 19.37o, 19.57o, 20.08o, 20.35o, 20.50o, 21.00o, 21.51o, 22.04o, 22.30o, 23.02o, 24.84o, 24.99o, 25.26o, 25.78o, 26.57o, 26.99o, 28.89o, 30.68o, and 33.16o.In some specific embodiments, the X-ray powder diffraction pattern of the formic acid solvated crystal O of the compound represented by formula (I) is shown in FIG. 18.In some specific embodiments, an X-ray powder diffraction pattern of the formic acid solvated crystal AF of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.19o, 7.48o, 8.32o, 12.49o, 13.46o, and 14.76o.In some specific embodiments, the X-ray powder diffraction pattern of the formic acid solvated crystal AF of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.19o, 7.48o, 8.32o, 12.49o, 12.97o, 13.46o, 14.76o, 17.56o, 23.59o, and 25.35o.In some specific embodiments, the X-ray powder diffraction pattern of the formic acid solvated crystal AF of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.93o, 6.19o, 7.48o, 8.32o, 11.30o, 11.65o, 12.49o, 12.97o, 13.46o, 14.76o, 17.56o, 17.81o, 18.48o, 19.37o, 20.48o, 21.57o, 22.75o, 23.59o, 24.93o, and 25.35o.In some specific embodiments, the X-ray powder diffraction pattern of the formic acid solvated crystal AF of the compound represented by formula (I) is shown in FIG. 24.In some specific embodiments, the ethanol solvated crystal of the compound represented by formula (I) is an ethanol solvated crystal R, and the ratio of the compound represented by formula (I) to ethanol is 1:0.3.In some specific embodiments, an X-ray powder diffraction pattern of the ethanol solvate crystal R of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 8.37o, 12.51o, 16.14o, 17.56o, 17.69o, 18.36o, 18.68o, 19.45o, 21.71o, 23.01o, and 24.14o.In some specific embodiments, the X-ray powder diffraction pattern of the ethanol solvate crystal R of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 8.37o, 12.51o, 15.04o, 16.14o, 16.59o, 17.56o, 17.69o, 18.36o, 18.68o, 19.45o, 21.71o, 23.01o, 24.14o, 24.98o, and 26.58o.In some specific embodiments, the X-ray powder diffraction pattern of the ethanol solvate crystal R of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 8.37o, 12.51o, 13.20o, 13.48o, 14.37o, 15.04o, 15.71o, 16.14o, 16.59o, 16.96o, 17.56o, 17.69o, 18.36o, 18.68o, 19.45o, 19.99o, 20.44o, 21.08o, 21.71o, 22.29o, 23.01o, 23.52o, 23.71o, 24.14o, 24.98o, 25.48o, 26.23o, 26.58o, 27.59o, 28.74o, 29.25o, and 30.32o.In some specific embodiments, the X-ray powder diffraction pattern of the ethanol solvate crystal R of the compound represented by formula (I) is shown in FIG. 28.In a fourth aspect of the present invention, provided is a eutectic crystal of the compound represented by formula (I),<!--[if gte vml 1]><v:shape id="_x0000_i1029" type="#_x0000_t75" style='width:114.75pt;height:99.75pt' o:ole=""><v:imagedata src="tmpusyf2wzl_files / image001.emz" o:title="" / >< / v:shape><![endif]--><!--[if !vml]--><!--[endif]--><!--[if gte mso 9]><xml><o:OLEObject Type="Embed" ProgID="ChemDraw.Document.6.0" ShapeID="_x0000_i1029" DrawAspect="Content" ObjectID="_1800177694">< / o:OLEObject>< / xml><![endif]--> (I).In some specific embodiments, the eutectic crystal of the compound represented by formula (I) is selected from: an oxalic acid eutectic crystal of the compound of formula (I), a fumaric acid eutectic crystal of the compound of formula (I), a citric acid eutectic crystal of the compound of formula (I), a malic acid eutectic crystal of the compound of formula (I), and a glycolic acid eutectic crystal of the compound of formula (I).In some specific embodiments, the oxalic acid eutectic crystal of the compound of formula (I) is selected from: an oxalic acid eutectic crystal Type A of the compound of formula (I) and an oxalic acid eutectic crystal Type B of the compound of formula (I), wherein the ratio of the compound of formula (I) to oxalic acid is 1:1.In some specific embodiments, an X-ray powder diffraction pattern of the oxalic acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.07o, 11.01o, 12.23o, 12.80o, 14.28o, 16.93o, and 21.76o.In some specific embodiments, the X-ray powder diffraction pattern of the oxalic acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.07o, 7.07o, 9.41o, 11.01o, 11.46o, 12.23o, 12.80o, 14.28o, 14.63o, 16.93o, 18.49o, 18.95o, and 21.76o.In some specific embodiments, the X-ray powder diffraction pattern of the oxalic acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 3.58o, 6.07o, 7.07o, 9.41o, 11.01o, 11.46o, 12.23o, 12.80o, 14.28o, 14.63o, 15.55o, 16.93o, 17.97o, 18.49o, 18.95o, 21.76o, 24.91o, and 25.72o.In some specific embodiments, the X-ray powder diffraction pattern of the oxalic acid eutectic crystal Type A of the compound of formula (I) is shown in FIG. 30.In some specific embodiments, an X-ray powder diffraction pattern of the oxalic acid eutectic crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.01o, 8.19o, 11.55o, 12.34o, 13.79o, 17.36o, 18.14o, 20.56o, 23.27o, 23.94o, and 25.24o.In some specific embodiments, the X-ray powder diffraction pattern of the oxalic acid eutectic crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 3.60o, 6.01o, 8.19o, 11.55o, 12.34o, 13.79o, 14.52o, 17.36o, 18.14o, 18.98o, 20.56o, 22.30o, 23.27o, 23.94o, and 25.24o.In some specific embodiments, the X-ray powder diffraction pattern of the oxalic acid eutectic crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 3.60o, 6.01o, 8.19o, 9.41o, 11.55o, 12.05o, 12.34o, 12.77o, 13.79o, 14.25o, 14.52o, 15.64o, 16.43o, 17.36o, 18.14o, 18.98o, 19.69o, 20.56o, 21.40o, 21.93o, 22.30o, 23.27o, 23.94o, 25.24o, 25.77o, and 27.76o.In some specific embodiments, the X-ray powder diffraction pattern of the oxalic acid eutectic crystal Type B of the compound of formula (I) is shown in FIG. 32.In some specific embodiments, the fumaric acid eutectic crystal of the compound of formula (I) is selected from: a fumaric acid eutectic crystal Type B and a fumaric acid eutectic crystal Type C, and the ratio of the compound of formula (I) to fumaric acid is 1:1.In some specific embodiments, an X-ray powder diffraction pattern of the fumaric acid eutectic crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.18o, 6.43o, 10.93o, 11.46o, 12.39o, 15.96o, 16.22o, 19.28o, and 22.09o.In some specific embodiments, the X-ray powder diffraction pattern of the fumaric acid eutectic crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 3.81o, 5.18o, 6.43o, 8.15o, 9.34o, 10.93o, 11.46o, 12.39o, 15.96o, 16.22o, 19.28o, and 22.09o.In some specific embodiments, the X-ray powder diffraction pattern of the fumaric acid eutectic crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 3.81o, 5.18o, 6.43o, 7.62o, 8.15o, 9.07o, 9.34o, 10.93o, 11.46o, 12.39o, 15.96o, 16.22o, 19.28o, and 22.09o.In some specific embodiments, the X-ray powder diffraction pattern of the fumaric acid eutectic crystal Type B of the compound of formula (I) is shown in FIG. 40.In one embodiment, an X-ray powder diffraction pattern of the fumaric acid eutectic crystal Type C has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.14o, 7.49o, 10.87o, 12.17o, 17.38o, 19.81o, 20.63o, 21.58o, 23.27o, 24.38o, and 25.39o.In one embodiment, the X-ray powder diffraction pattern of the fumaric acid eutectic crystal Type C has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.14o, 7.49o, 8.23o, 10.87o, 12.17o, 16.43o, 17.38o, 17.69o, 19.81o, 20.63o, 21.11o, 21.58o, 23.27o, 24.38o, 25.39o, 28.27o, 29.37o, and 31.28o.In one embodiment, the X-ray powder diffraction pattern of the fumaric acid eutectic crystal Type C has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.14o, 7.49o, 8.23o, 10.87o, 12.17o, 13.24o, 13.96o, 16.43o, 17.38o, 17.69o, 18.74o, 19.81o, 19.97o, 20.63o, 21.11o, 21.58o, 23.27o, 23.54o, 24.38o, 25.39o, 26.48o, 28.27o, 29.37o, 30.89o, 31.28o, and 32.60o.In one embodiment, the X-ray powder diffraction pattern of the fumaric acid eutectic crystal Type C is shown in FIG. 42.In some specific embodiments, the citric acid eutectic crystal of the compound of formula (I) is a citric acid eutectic crystal Type A of the compound of formula (I), and the ratio of the compound of formula (I) to citric acid is 1:1.In some specific embodiments, an X-ray powder diffraction pattern of the citric acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.56o, 6.52o, 9.85o, 14.27o, 14.62o, 16.60o, 17.73o, 19.71o, 19.86o, 24.36o, and 26.42o.In some specific embodiments, the X-ray powder diffraction pattern of the citric acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.56o, 6.52o, 9.85o, 13.20o, 13.46o, 14.27o, 14.62o, 15.78o, 16.60o, 17.73o, 19.71o, 19.86o, 24.36o, 25.16o, and 26.42o.In some specific embodiments, the X-ray powder diffraction pattern of the citric acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.56o, 6.52o, 7.10o, 9.85o, 13.20o, 13.46o, 14.27o, 14.62o, 15.41o, 15.78o, 16.29o, 16.60o, 17.73o, 19.31o, 19.71o, 19.86o, 23.15o, 24.36o, 25.16o, and 26.42o.In some specific embodiments, the X-ray powder diffraction pattern of the citric acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.56o, 6.52o, 7.10o, 9.85o, 11.00o, 12.76o, 13.20o, 13.46o, 14.27o, 14.62o, 15.41o, 15.78o, 16.29o, 16.60o, 17.73o, 19.31o, 19.71o, 19.86o, 23.15o, 23.51o, 24.36o, 25.16o, 25.56o, 25.70o, 26.42o, 27.08o, 27.53o, 27.74o, 28.08o, and 32.03o.In some specific embodiments, the X-ray powder diffraction pattern of the citric acid eutectic crystal Type A of the compound of formula (I) is shown in FIG. 58.In some specific embodiments, the malic acid eutectic crystal of the compound of formula (I) is a malic acid eutectic crystal Type A of the compound of formula (I), and the ratio of the compound of formula (I) to malic acid is 1:1.In some specific embodiments, an X-ray powder diffraction pattern of the malic acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.14o, 8.77o, 8.99o, 9.90o, 11.59o, 11.84o, 17.27o, 19.91o, 20.22o, 21.09o, 23.74o, and 25.22o.In some specific embodiments, the X-ray powder diffraction pattern of the malic acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.14o, 8.77o, 8.99o, 9.90o, 11.59o, 11.84o, 17.27o, 18.02o, 19.21o, 19.91o, 20.22o, 21.09o, 22.98o, 23.74o, 24.42o, and 25.22o.In some specific embodiments, the X-ray powder diffraction pattern of the malic acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.14o, 8.77o, 8.99o, 9.90o, 11.59o, 11.84o, 13.90o, 14.72o, 15.83o, 17.27o, 18.02o, 19.21o, 19.91o, 20.22o, 21.09o, 22.98o, 23.74o, 24.42o, and 25.22o.In some specific embodiments, the X-ray powder diffraction pattern of the malic acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.14o, 8.77o, 8.99o, 9.90o, 11.59o, 11.84o, 13.90o, 14.72o, 15.83o, 17.27o, 18.02o, 18.49o, 19.21o, 19.91o, 20.22o, 20.49o, 21.09o, 22.32o, 22.98o, 23.74o, 24.42o, 25.22o, 25.58o, 26.30o, 27.04o, 27.86o, 28.46o, 29.20o, 29.84o, 31.18o, 31.42o, 34.27o, and 34.82o.In some specific embodiments, the X-ray powder diffraction pattern of the malic acid eutectic crystal Type A of the compound of formula (I) is shown in FIG. 60.In some specific embodiments, the glycolic acid eutectic crystal of the compound of formula (I) is selected from: a glycolic acid eutectic crystal Type A of the compound of formula (I) and a glycolic acid eutectic crystal Type B of the compound of formula (I), wherein the ratio of the compound of formula (I) to glycolic acid is 1:1.In some specific embodiments, an X-ray powder diffraction pattern of the glycolic acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.61o, 6.83o, 8.27o, 11.25o, 13.73o, 14.63o, 16.94o, 19.79o, and 23.23o.In some specific embodiments, the X-ray powder diffraction pattern of the glycolic acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.61o, 6.83o, 8.27o, 11.25o, 11.50o, 13.73o, 14.63o, 16.63o, 16.94o, 19.79o, 20.37o, 21.33o, 23.23o, and 24.68.In some specific embodiments, the X-ray powder diffraction pattern of the glycolic acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.61o, 6.83o, 7.77o, 8.27o, 9.32o, 9.64o, 11.25o, 11.50o, 12.02o, 13.73o, 14.63o, 15.33o, 16.63o, 16.94o, 17.80o, 19.79o, 20.37o, 21.33o, 21.58o, 22.10o, 22.64o, 23.23o, 24.21o, 24.68o, 25.33o, 26.16o, 27.99o, and 32.77o.In some specific embodiments, the X-ray powder diffraction pattern of the glycolic acid eutectic crystal Type A of the compound of formula (I) is shown in FIG. 66.In some specific embodiments, an X-ray powder diffraction pattern of the glycolic acid eutectic crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.44o, 6.70o, 8.29o, 10.96o, 13.50o, 14.25o, 16.48o, 20.83o, and 25.06o.In some specific embodiments, the X-ray powder diffraction pattern of the glycolic acid eutectic crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.44o, 6.70o, 8.29o, 10.96o, 11.36, 13.50o, 14.25o, 16.48o, 19.66o, 19.92o, 20.48o, 20.83o, and 25.06o.In some specific embodiments, the X-ray powder diffraction pattern of the glycolic acid eutectic crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.44o, 6.70o, 8.29o, 10.96o, 11.36o, 12.07o, 13.50o, 14.25o, 16.48o, 19.66o, 19.92o, 20.48o, 20.83o, 22.87, 23.43, and 25.06o.In some specific embodiments, the X-ray powder diffraction pattern of the glycolic acid eutectic crystal Type B of the compound of formula (I) is shown in FIG. 68.In a fourth aspect of the present invention, provided is a salt form of the compound represented by formula (I),<!--[if gte vml 1]><v:shape id="_x0000_i1030" type="#_x0000_t75" style='width:114.75pt;height:99.75pt' o:ole=""><v:imagedata src="tmpusyf2wzl_files / image001.emz" o:title="" / >< / v:shape><![endif]--><!--[if !vml]--><!--[endif]--><!--[if gte mso 9]><xml><o:OLEObject Type="Embed" ProgID="ChemDraw.Document.6.0" ShapeID="_x0000_i1030" DrawAspect="Content" ObjectID="_1800177695">< / o:OLEObject>< / xml><![endif]--> (I).In some specific embodiments, the salt form of the compound represented by formula (I) is selected from: a toluenesulfonate of the compound, a methanesulfonate of the compound, a potassium salt of the compound, a maleate of the compound, a sodium salt of the compound, and a hydrochloride of the compound.In some specific embodiments, in the p-toluenesulfonate of the compound represented by formula (I), the ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1:1.In some specific embodiments, in the methanesulfonate of the compound represented by formula (I), the ratio of the compound represented by formula (I) to methanesulfonic acid is 1:1-1.2.In some specific embodiments, the potassium salt of the compound represented by formula (I) has the structure <!--[if gte vml 1]><v:shape id="_x0000_i1031" type="#_x0000_t75" style='width:111pt;height:95.25pt' o:ole=""><v:imagedata src="tmpusyf2wzl_files / image006.emz" o:title="" / >< / v:shape><![endif]--><!--[if !vml]--><!--[endif]--><!--[if gte mso 9]><xml><o:OLEObject Type="Embed" ProgID="ChemDraw.Document.6.0" ShapeID="_x0000_i1031" DrawAspect="Content" ObjectID="_1800177696">< / o:OLEObject>< / xml><![endif]-->.In some specific embodiments, in the maleate of the compound represented by formula (I), the ratio of the compound represented by formula (I) to maleic acid is 1:1.In some specific embodiments, the sodium salt of the compound represented by formula (I) has the structure <!--[if gte vml 1]><v:shape id="_x0000_i1032" type="#_x0000_t75" style='width:108.75pt;height:93.75pt' o:ole=""><v:imagedata src="tmpusyf2wzl_files / image008.emz" o:title="" / >< / v:shape><![endif]--><!--[if !vml]--><!--[endif]--><!--[if gte mso 9]><xml><o:OLEObject Type="Embed" ProgID="ChemDraw.Document.6.0" ShapeID="_x0000_i1032" DrawAspect="Content" ObjectID="_1800177697">< / o:OLEObject>< / xml><![endif]-->.In some specific embodiments, in the hydrochloride of the compound represented by formula (I), the ratio of the compound represented by formula (I) to hydrochloric acid is 1:1.In a fifth aspect of the present invention, provided is a salt-form crystal of the compound represented by formula (I),<!--[if gte vml 1]><v:shape id="_x0000_i1033" type="#_x0000_t75" style='width:114.75pt;height:99.75pt' o:ole=""><v:imagedata src="tmpusyf2wzl_files / image001.emz" o:title="" / >< / v:shape><![endif]--><!--[if !vml]--><!--[endif]--><!--[if gte mso 9]><xml><o:OLEObject Type="Embed" ProgID="ChemDraw.Document.6.0" ShapeID="_x0000_i1033" DrawAspect="Content" ObjectID="_1800177698">< / o:OLEObject>< / xml><![endif]--> (I).In some specific embodiments, the salt-form crystal of the compound represented by formula (I) is selected from:a p-toluenesulfonate crystal of the compound, wherein the ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1:1;a methanesulfonate crystal of the compound, wherein the ratio of the compound represented by formula (I) to methanesulfonic acid is 1:1-1.2;a potassium salt crystal of the compound, having the structure <!--[if gte vml 1]><v:shape id="_x0000_i1034" type="#_x0000_t75" style='width:111pt;height:95.25pt' o:ole=""><v:imagedata src="tmpusyf2wzl_files / image006.emz" o:title="" / >< / v:shape><![endif]--><!--[if !vml]--><!--[endif]--><!--[if gte mso 9]><xml><o:OLEObject Type="Embed" ProgID="ChemDraw.Document.6.0" ShapeID="_x0000_i1034" DrawAspect="Content" ObjectID="_1800177699">< / o:OLEObject>< / xml><![endif]-->;a maleate crystal of the compound, wherein the ratio of the compound represented by formula (I) to maleic acid is 1:1;a sodium salt crystal of the compound, having the structure <!--[if gte vml 1]><v:shape id="_x0000_i1035" type="#_x0000_t75" style='width:108.75pt;height:93.75pt' o:ole=""><v:imagedata src="tmpusyf2wzl_files / image008.emz" o:title="" / >< / v:shape><![endif]--><!--[if !vml]--><!--[endif]--><!--[if gte mso 9]><xml><o:OLEObject Type="Embed" ProgID="ChemDraw.Document.6.0" ShapeID="_x0000_i1035" DrawAspect="Content" ObjectID="_1800177700">< / o:OLEObject>< / xml><![endif]-->; anda hydrochloride crystal of the compound, wherein the ratio of the compound represented by formula (I) to hydrochloric acid is 1:1.In some specific embodiments, the p-toluenesulfonate crystal of the compound of formula (I) is selected from a p-toluenesulfonate crystal Type A of the compound, a p-toluenesulfonate crystal Type B of the compound, and a p-toluenesulfonate crystal Type C of the compound, wherein the ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1:1.In some specific embodiments, an X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.41o, 9.57o, 9.92o, 16.06o, 16.94o, 19.70o, 20.44o, 22.07o, and 26.24o.In some specific embodiments, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.41o, 9.14o, 9.57o, 9.92o, 11.25o, 12.95o, 14.45o, 16.06o, 16.94o, 19.70o, 20.44o, 21.30o, 22.07o, 24.82o, 25.52o, and 26.24o.In some specific embodiments, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.41o, 9.14o, 9.57o, 9.92o, 10.98o, 11.25o, 12.95o, 14.33o, 14.45o, 15.05o, 15.21o, 15.82o, 16.06o, 16.94o, 17.56o, 17.77o, 18.07o, 18.38o, 19.23o, 19.41o, 19.70o, 20.44o, 21.08o, 21.30o, 22.07o, 22.41o, 22.67o, 23.19o, 23.46o, 24.82o, 25.52o, 26.02o, 26.24o, 28.12o, 28.72o, 30.18o, 30.74o, and 32.03o.In some specific embodiments, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type A of the compound of formula (I) is shown in FIG. 34.In some specific embodiments, an X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.35o, 6.93o, 7.63o, 14.59o, 16.79o, and 20.79o.In some specific embodiments, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.35o, 6.93o, 7.63o, 11.29o, 14.59o, 16.79o, 17.72o, 20.79o, 22.25o, and 26.56o.In some specific embodiments, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.35o, 6.93o, 7.63o, 8.29o, 11.29o, 12.72o, 14.59o, 16.79o, 17.72o, 19.33o, 20.79o, 22.25o, 23.05o, 25.19o, 26.56o, and 27.84o.In some specific embodiments, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type B of the compound of formula (I) is shown in FIG. 36.In some specific embodiments, an X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type C of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.19o, 6.87o, 10.06o, 13.79o, 16.62o, 16.93o, 20.44o, 24.53o, and 26.12o.In some specific embodiments, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type C of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.19o, 6.87o, 10.06o, 13.79o, 14.79o, 16.62o, 16.93o, 17.23o, 20.44o, 21.03o, 24.53o, 24.93o, and 26.12o.In some specific embodiments, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type C of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.19o, 6.87o, 10.06o, 12.06o, 12.72o, 12.95o, 13.58o, 13.79o, 14.17o, 14.46o, 14.79o, 16.62o, 16.93o, 17.23o, 18.76o, 19.36o, 20.44o, 21.03o, 21.55o, 21.83o, 22.10o, 23.31o, 23.51o, 23.73o, 24.13o, 24.53o, 24.93o, 25.60o, 26.12o, 27.26o, 27.76o, 29.50o, 29.84o, and 30.52o.In some specific embodiments, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type C of the compound of formula (I) is shown in FIG. 38.In some specific embodiments, the methanesulfonate crystal of the compound of formula (I) is selected from a methanesulfonate crystal Type A of the compound, a methanesulfonate crystal Type B of the compound, and a methanesulfonate crystal Type C of the compound, wherein the ratio of the compound represented by formula (I) to methanesulfonic acid is 1:1-1.2.In some specific embodiments, the methanesulfonate crystal of the compound of formula (I) is a methanesulfonate crystal Type A of the compound, and the ratio of the compound represented by formula (I) to methanesulfonic acid is 1:1.In some specific embodiments, an X-ray powder diffraction pattern of the methanesulfonate crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 8.09o, 9.60o, 11.06o, 12.57o, 14.33o, 14.55o, 16.93o, 19.32o, 19.64o, 20.19o, 20.31o, 21.05o, and 26.42o.In some specific embodiments, the X-ray powder diffraction pattern of the methanesulfonate crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 8.09o, 9.60o, 10.75o, 11.06o, 12.57o, 14.33o, 14.55o, 16.52o, 16.93o, 19.32o, 19.64o, 20.19o, 20.31o, 21.05o, 21.59o, 22.98o, 24.72o, 26.42o, 27.00o, and 28.30o.In some specific embodiments, the X-ray powder diffraction pattern of the methanesulfonate crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 8.09o, 8.69o, 9.60o, 10.75o, 11.06o, 12.02o, 12.57o, 13.85o, 14.33o, 14.55o, 15.33o, 15.89o, 16.52o, 16.93o, 17.39o, 17.67o, 17.93o, 19.32o, 19.64o, 19.96o, 20.19o, 20.31o, 20.65o, 21.05o, 21.59o, 21.78o, 22.25o, 22.51o, 22.70o, 22.98o, 24.52o, 24.72o, 25.26o, 25.89o, 26.42o, 27.00o, 27.41o, 28.30o, 28.55o, 29.47o, 31.47o, and 33.70o.In some specific embodiments, the X-ray powder diffraction pattern of the methanesulfonate crystal Type A of the compound of formula (I) is shown in FIG. 44.In some specific embodiments, the methanesulfonate crystal of the compound of formula (I) is a methanesulfonate crystal Type B of the compound, and the ratio of the compound represented by formula (I) to methanesulfonic acid is 1:1.2.In some specific embodiments, an X-ray powder diffraction pattern of the methanesulfonate crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.74o, 5.89o, 11.53o, 11.93o, 12.47o, 12.90o, 14.06o, 15.01o, 17.14o, and 25.52o.In some specific embodiments, the X-ray powder diffraction pattern of the methanesulfonate crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.74o, 5.89o, 7.66o, 11.53o, 11.93o, 12.47o, 12.90o, 14.06o, 15.01o, 17.14o, 22.60o, and 25.52o.In some specific embodiments, the X-ray powder diffraction pattern of the methanesulfonate crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.74o, 5.89o, 7.66o, 7.95o, 8.95o, 10.21o, 11.53o, 11.93o, 12.47o, 12.90o, 14.06o, 15.01o, 17.14o, 17.99o, 20.49o, 22.60o, 23.90o, 25.52o, and 26.39o.In some specific embodiments, the X-ray powder diffraction pattern of the methanesulfonate crystal Type B of the compound of formula (I) is shown in FIG. 46.In some specific embodiments, the methanesulfonate crystal of the compound of formula (I) is a methanesulfonate crystal Type C of the compound, and the ratio of the compound represented by formula (I) to methanesulfonic acid is 1:1.In some specific embodiments, an X-ray powder diffraction pattern of the methanesulfonate crystal Type C of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.32o, 8.45o, 11.84o, 17.01o, 18.49o, 21.30o, and 22.98o.In some specific embodiments, the X-ray powder diffraction pattern of the methanesulfonate crystal Type C of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.32o, 8.45o, 10.30o, 11.84o, 16.06o, 17.01o, 18.49o, 21.30o, 22.98o, and 24.30o.In some specific embodiments, the X-ray powder diffraction pattern of the methanesulfonate crystal Type C of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.32o, 8.45o, 10.30o, 11.84o, 14.48o, 14.78o, 15.28o, 16.06o, 17.01o, 18.49o, 20.46o, 20.91o, 21.30o, 22.98o, 23.51o, 24.30o, 24.85o, 25.44o, 25.83o, 28.47o, and 30.85o.In some specific embodiments, the X-ray powder diffraction pattern of the methanesulfonate crystal Type C of the compound of formula (I) is shown in FIG. 48.In some specific embodiments, the potassium salt crystal of the compound of formula (I) is a potassium salt crystal Type A of the compound.In some specific embodiments, an X-ray powder diffraction pattern of the potassium salt crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.74o, 6.68o, 7.96o, 13.54o, 14.04o, 17.78o, 20.14o, and 23.29o.In some specific embodiments, the X-ray powder diffraction pattern of the potassium salt crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.74o, 6.68o, 7.96o, 11.78o, 13.54o, 14.04o, 15.33o, 17.78o, 19.45o, 20.14o, 23.29o, 24.72o, 26.92o, and 28.29o.In some specific embodiments, the X-ray powder diffraction pattern of the potassium salt crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.74o, 6.68o, 7.96o, 11.52o, 11.78o, 13.54o, 14.04o, 14.44o, 15.33o, 16.22o, 16.71o, 17.43o, 17.78o, 18.20o, 18.40o, 18.86o, 19.45o, 20.14o, 20.70o, 22.75o, 23.29o, 24.15o, 24.72o, 26.39o, 26.92o, 27.37o, 27.62o, 28.29o, 31.39o, and 36.10o.In some specific embodiments, the X-ray powder diffraction pattern of the potassium salt crystal Type A of the compound of formula (I) is shown in FIG. 50.In some specific embodiments, the maleate crystal of the compound of formula (I) is selected from: a maleate crystal Type A of the compound and a maleate crystal Type B of the compound, wherein the ratio of the compound of formula (I) to maleic acid is 1:1.In some specific embodiments, an X-ray powder diffraction pattern of the maleate crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.26o, 4.76o, 7.08o, 7.96o, 8.54o, 9.53o, 10.18o, 10.93o, 14.34o, 15.03o, 15.99o, and 20.50o.In some specific embodiments, the X-ray powder diffraction pattern of the maleate crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.26o, 4.76o, 7.08o, 7.96o, 8.54o, 9.53o, 10.18o, 10.93o, 13.89o, 14.34o, 15.03o, 15.99o, 20.50o, 21.49o, and 24.03o.In some specific embodiments, the X-ray powder diffraction pattern of the maleate crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.26o, 4.76o, 7.08o, 7.96o, 8.54o, 9.53o, 10.18o, 10.93o, 12.41o, 13.89o, 14.34o, 15.03o, 15.99o, 17.93o, 20.50o, 21.49o, 23.55o, and 24.03o.In some specific embodiments, the X-ray powder diffraction pattern of the maleate crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.26o, 4.76o, 7.08o, 7.96o, 8.54o, 9.53o, 10.18o, 10.93o, 12.41o, 13.89o, 14.34o, 15.03o, 15.99o, 17.93o, 20.50o, 21.49o, 21.97o, 23.55o, 24.03o, 25.19o, 25.57o, and 26.00o.In some specific embodiments, the X-ray powder diffraction pattern of the maleate crystal Type A of the compound of formula (I) is shown in FIG. 52.In some specific embodiments, an X-ray powder diffraction pattern of the maleate crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.34o, 4.79o, 5.27o, 7.20o, 7.86o, 10.22o, 10.56o, 11.08o, 14.73o, 15.20o, 16.14o, and 20.50o.In some specific embodiments, the X-ray powder diffraction pattern of the maleate crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.34o, 4.79o, 5.27o, 7.20o, 7.86o, 10.22o, 10.56o, 11.08o, 11.81o, 14.44o, 14.73o, 15.20o, 16.14o, and 20.50o.In some specific embodiments, the X-ray powder diffraction pattern of the maleate crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.34o, 4.79o, 5.27o, 7.20o, 7.86o, 8.63o, 9.60o, 10.22o, 10.56o, 11.08o, 11.81o, 13.94o, 14.44o, 14.73o, 15.20o, 16.14o, 20.50o, 21.25o, 21.83o, and 26.32o.In some specific embodiments, the X-ray powder diffraction pattern of the maleate crystal Type B of the compound of formula (I) is shown in FIG. 54.In some specific embodiments, the sodium salt crystal of the compound of formula (I) is a sodium salt crystal Type B of the compound.In some specific embodiments, an X-ray powder diffraction pattern of the sodium salt crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.01o, 6.61o, 7.94o, 11.88o, 12.48o, 13.10o, 13.70o, 18.31o, 19.98o, 21.19o, 22.35o, 25.36o, and 26.27o.In some specific embodiments, the X-ray powder diffraction pattern of the sodium salt crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.01o, 6.61o, 7.94o, 11.88o, 12.48o, 13.10o, 13.31o, 13.70o, 16.52o, 17.48o, 18.31o, 19.98o, 21.19o, 22.35o, 24.81o, 25.36o, and 26.27o.In some specific embodiments, the X-ray powder diffraction pattern of the sodium salt crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.01o, 6.61o, 7.94o, 11.88o, 12.48o, 13.10o, 13.31o, 13.70o, 14.96o, 15.25o, 16.52o, 17.48o, 18.31o, 19.07o, 19.98o, 20.59o, 21.19o, 22.35o, 23.86o, 24.81o, 25.36o, 26.27o, 27.78o, 28.28o, 31.15o, and 31.79o.In some specific embodiments, the X-ray powder diffraction pattern of the sodium salt crystal Type B of the compound of formula (I) is shown in FIG. 56.In some specific embodiments, the hydrochloride crystal of the compound of formula (I) is selected from a hydrochloride crystal Type A of the compound and a hydrochloride crystal Type B of the compound, wherein the ratio of the compound of formula (I) to hydrochloric acid is 1:1.In some specific embodiments, an X-ray powder diffraction pattern of the hydrochloride crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.90o, 7.42o, 7.74o, 10.96o, 14.07o, 14.96o, 18.01o, 25.14o, and 26.42o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrochloride crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.90o, 7.42o, 7.74o, 10.96o, 11.56o, 12.15o, 14.07o, 14.96o, 18.01o, 21.93o, 23.42o, 25.14o, and 26.42o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrochloride crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.90o, 7.42o, 7.74o, 10.96o, 11.56o, 12.15o, 13.39o, 14.07o, 14.96o, 17.60o, 18.01o, 19.26o, 19.70o, 21.55o, 21.93o, 23.42o, 25.14o, 25.56o, 26.42o, 27.71o, 28.84o, and 29.26o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrochloride crystal Type A of the compound of formula (I) is shown in FIG. 62.In some specific embodiments, an X-ray powder diffraction pattern of the hydrochloride crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.48o, 7.20o, 7.90o, 14.16o, 14.48o, 15.68o, 17.31o, 21.76o, and 26.53o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrochloride crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.42o, 6.48o, 7.20o, 7.90o, 12.85o, 13.01o, 14.16o, 14.48o, 15.68o, 17.31o, 19.36o, 21.76o, 22.91o, and 26.53o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrochloride crystal Type B of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.80o, 5.42o, 6.48o, 7.20o, 7.90o, 10.00o, 13.50o, 10.39o, 12.85o, 13.01o, 14.16o, 14.48o, 15.68o, 17.31o, 19.36o, 19.64o, 21.76o, 22.91o, 23.86o, 24.40o, 25.72o, 25.95o, 26.14o, 26.53o, 28.53o, and 31.86o.In some specific embodiments, the X-ray powder diffraction pattern of the hydrochloride crystal Type B of the compound of formula (I) is shown in FIG. 64.Notes:The ratios of the solvate crystals, the eutectic crystals, or the salt-form crystals in the present invention are molar ratios, unless otherwise indicated.The terms “solvation complex” and “solvate” in the present invention have the same meaning and are interchangeable.The terms “crystal” and “crystalline form” in the present invention have the same meaning and are interchangeable.Effects of the invention:The present invention provides a variety of new crystalline forms, salt forms, and eutectic crystalline forms of the compound represented by formula (I) in order to meet different clinical needs.BRIEF DESCRIPTION OF THE DRAWINGSFIG. 1 shows an XPRD pattern of a methanol solvated crystal A of the compound represented by formula (I).FIG. 2 shows a proton nuclear magnetic resonance spectrum of the methanol solvated crystal A of the compound represented by formula (I).FIG. 3 shows an XPRD pattern of a hydrate crystal AA of the compound represented by formula (I).FIG. 4 shows a proton nuclear magnetic resonance spectrum of the hydrate crystal AA of the compound represented by formula (I).FIG. 5 shows an XPRD pattern of a methanol solvated crystal AE of the compound represented by formula (I).FIG. 6 shows a proton nuclear magnetic resonance spectrum of the methanol solvated crystal AE of the compound represented by formula (I).FIG. 7 shows an XPRD pattern of a non-solvate crystal AH of the compound represented by formula (I).FIG. 8 shows a proton nuclear magnetic resonance spectrum of the non-solvate crystal AH of the compound represented by formula (I).FIG. 9 shows a differential scanning calorimetry analysis curve plot of the non-solvate crystal AH of the compound represented by formula (I).FIG. 10 shows a thermogravimetric analysis curve plot of the non-solvate crystal AH of the compound represented by formula (I).FIG. 11 shows an XPRD pattern of a non-solvate crystal E (crystalline form E) of the compound represented by formula (I).FIG. 12 shows a proton nuclear magnetic resonance spectrum of the non-solvate crystal E (crystalline form E) of the compound represented by formula (I).FIG. 13 shows a differential scanning calorimetry analysis curve plot of the non-solvate crystal E (crystalline form E) of the compound represented by formula (I).FIG. 14 shows a thermogravimetric analysis curve plot of the non-solvate crystal E (crystalline form E) of the compound represented by formula (I).FIG. 15 shows an X-ray single-crystal diffraction pattern of the non-solvate crystal E (crystalline form E) of the compound represented by formula (I).FIG. 16 shows an XPRD pattern of a formic acid solvated crystal F of the compound represented by formula (I).FIG. 17 shows a proton nuclear magnetic resonance spectrum of the formic acid solvated crystal F of the compound represented by formula (I).FIG. 18 shows an XPRD pattern of a formic acid solvation complex crystal O of the compound represented by formula (I).FIG. 19 shows a proton nuclear magnetic resonance spectrum of the formic acid solvation complex crystal O of the compound represented by formula (I).FIG. 20 shows an XPRD pattern of a hydrate crystal T of the compound represented by formula (I).FIG. 21 shows a proton nuclear magnetic resonance spectrum of the hydrate crystal T of the compound represented by formula (I).FIG. 22 shows an XPRD pattern of a hydrate crystal V of the compound represented by formula (I).FIG. 23 shows a proton nuclear magnetic resonance spectrum of the hydrate crystal V of the compound represented by formula (I).FIG. 24 shows an XPRD pattern of a formic acid solvation complex crystal AF of the compound represented by formula (I).FIG. 25 shows a proton nuclear magnetic resonance spectrum of the formic acid solvation complex crystal AF of the compound represented by formula (I).FIG. 26 shows an XPRD pattern of a hydrate crystal L of the compound represented by formula (I).FIG. 27 shows a proton nuclear magnetic resonance spectrum of the hydrate crystal L of the compound represented by formula (I).FIG. 28 shows an XPRD pattern of an ethanol solvation complex crystal R of the compound represented by formula (I).FIG. 29 shows a proton nuclear magnetic resonance spectrum of the ethanol solvation complex crystal R of the compound represented by formula (I).FIG. 30 shows an XPRD pattern of an oxalic acid eutectic crystal Type A of the compound represented by formula (I).FIG. 31 shows a proton nuclear magnetic resonance spectrum of the oxalic acid eutectic crystal Type A of the compound represented by formula (I).FIG. 32 shows an XPRD pattern of an oxalic acid eutectic crystal Type B of the compound represented by formula (I).FIG. 33 shows a proton nuclear magnetic resonance spectrum of the oxalic acid eutectic crystal Type B of the compound represented by formula (I).FIG. 34 shows an XPRD pattern of a p-toluenesulfonate crystal Type A of the compound represented by formula (I).FIG. 35 shows a proton nuclear magnetic resonance spectrum of the p-toluenesulfonate crystal Type A of the compound represented by formula (I).FIG. 36 shows an XPRD pattern of a p-toluenesulfonate crystal Type B of the compound represented by formula (I).FIG. 37 shows a proton nuclear magnetic resonance spectrum of the p-toluenesulfonate crystal Type B of the compound represented by formula (I).FIG. 38 shows an XPRD pattern of a p-toluenesulfonate crystal Type C of the compound represented by formula (I).FIG. 39 shows a proton nuclear magnetic resonance spectrum of the p-toluenesulfonate crystal Type C of the compound represented by formula (I).FIG. 40 shows an XPRD pattern of a fumaric acid eutectic crystal Type B of the compound represented by formula (I).FIG. 41 shows a proton nuclear magnetic resonance spectrum of the fumaric acid eutectic crystal Type B of the compound represented by formula (I).FIG. 42 shows an XPRD pattern of a fumaric acid eutectic crystal Type C of the compound represented by formula (I).FIG. 43 shows a proton nuclear magnetic resonance spectrum of the fumaric acid eutectic crystal Type C of the compound represented by formula (I).FIG. 44 shows an XPRD pattern of a methanesulfonate crystal Type A of the compound represented by formula (I).FIG. 45 shows a proton nuclear magnetic resonance spectrum of the methanesulfonate crystal Type A of the compound represented by formula (I).FIG. 46 shows an XPRD pattern of a methanesulfonate crystal Type B of the compound represented by formula (I).FIG. 47 shows a proton nuclear magnetic resonance spectrum of the methanesulfonate crystal Type B of the compound represented by formula (I).FIG. 48 shows an XPRD pattern of a methanesulfonate crystal Type C of the compound represented by formula (I).FIG. 49 shows a proton nuclear magnetic resonance spectrum of the methanesulfonate crystal Type C of the compound represented by formula (I).FIG. 50 shows an XPRD pattern of a potassium salt crystal Type A of the compound represented by formula (I).FIG. 51 shows a proton nuclear magnetic resonance spectrum of the potassium salt crystal Type A of the compound represented by formula (I).FIG. 52 shows an XPRD pattern of a maleate crystal Type A of the compound represented by formula (I).FIG. 53 shows a proton nuclear magnetic resonance spectrum of the maleate crystal Type A of the compound represented by formula (I).FIG. 54 shows an XPRD pattern of a maleate crystal Type B of the compound represented by formula (I).FIG. 55 shows a proton nuclear magnetic resonance spectrum of the maleate crystal Type B of the compound represented by formula (I).FIG. 56 shows an XPRD pattern of a sodium salt crystal Type B of the compound represented by formula (I).FIG. 57 shows a proton nuclear magnetic resonance spectrum of the sodium salt crystal Type B of the compound represented by formula (I).FIG. 58 shows an XPRD pattern of a citrate eutectic Type A of the compound represented by formula (I).FIG. 59 shows a proton nuclear magnetic resonance spectrum of the citrate eutectic Type A of the compound represented by formula (I).FIG. 60 shows an XPRD pattern of a malic acid eutectic crystal Type A of the compound represented by formula (I).FIG. 61 shows a proton nuclear magnetic resonance spectrum of the malic acid eutectic crystal Type A of the compound represented by formula (I).FIG. 62 shows an XPRD pattern of a hydrochloride Type A of the compound represented by formula (I).FIG. 63 shows a proton nuclear magnetic resonance spectrum of the hydrochloride Type A of the compound represented by formula (I).FIG. 64 shows an XPRD pattern of a hydrochloride Type B of the compound represented by formula (I).FIG. 65 shows a proton nuclear magnetic resonance spectrum of the hydrochloride Type B of the compound represented by formula (I).FIG. 66 shows an XPRD pattern of a glycolic acid eutectic crystal Type A of the compound represented by formula (I).FIG. 67 shows a proton nuclear magnetic resonance spectrum of the glycolic acid eutectic crystal Type A of the compound represented by formula (I).FIG. 68 shows an XPRD pattern of a glycolic acid eutectic crystal Type B of the compound represented by formula (I).FIG. 69 shows a proton nuclear magnetic resonance spectrum of the glycolic acid eutectic crystal Type B of the compound represented by formula (I).FIG. 70 shows an XRPD pattern of the solid obtained in Example 34.FIG. 71 shows changes in the mass of samples of the non-solvated crystalline form E of the compound of formula (I) under different humidity conditions in a DVS experiment in Example 35.FIG. 72 shows an XRPD pattern of a sample of the non-solvated crystalline form E of the compound of formula (I) after a DVS experiment in Example 35.FIG. 73 shows changes in the mass of samples of the non-solvated crystalline form AH of the compound of formula (I) under different humidity conditions in a DVS experiment in Example 36.FIG. 74 shows an XRPD pattern of a sample of the non-solvated crystalline form AH of the compound of formula (I) after a DVS experiment in Example 36.FIG. 75 shows changes in the mass of samples of the maleate crystalline form Type A of the compound of formula (I) under different humidity conditions in a DVS experiment in Example 37.FIG. 76 shows an XRPD pattern of a sample of the maleate crystalline form Type A of the compound of formula (I) after a DVS experiment in Example 37.FIG. 77 shows changes in the mass of samples of the citric acid eutectic crystalline form Type A of the compound of formula (I) under different humidity conditions in a DVS experiment in Example 38.FIG. 78 shows an XRPD pattern of a sample of the citric acid eutectic crystalline form Type A of the compound of formula (I) after a DVS experiment in Example 38.FIG. 79 shows changes in the mass of samples of the malic acid eutectic crystalline form Type A of the compound of formula (I) under different humidity conditions in a DVS experiment in Example 39.FIG. 80 shows an XRPD pattern of a sample of the malic acid eutectic crystalline form Type A of the compound of formula (I) after a DVS experiment in Example 39.FIG. 81 shows XRPD patterns of samples of the non-solvated crystalline form E of the compound of formula (I) after stability testing under different conditions in Example 40.FIG. 82 shows XRPD patterns of samples of the non-solvated crystalline form AH of the compound of formula (I) after stability testing under different conditions in Example 41.FIG. 83 shows XRPD patterns of samples of the maleate crystalline form Type A of the compound of formula (I) after stability testing under different conditions in Example 42.FIG. 84 shows XRPD patterns of samples of the citric acid eutectic crystalline form Type A of the compound of formula (I) after stability testing under different conditions in Example 43.FIG. 85 shows XRPD patterns of samples of the malic acid eutectic crystalline form Type A of the compound of formula (I) after stability testing under different conditions in Example 44. DETAILED DESCRIPTIONThe present invention is further illustrated using the following examples, and it should be understood that the terms used herein aim to describe specific embodiments and are not intended to be limiting. The numerical ranges described in the specification, such as units of measurement, reaction conditions, physical states, or percentages of compounds, are intended to provide an unambiguous written reference. One skilled in the art can practice this patent using temperatures, concentrations, amounts, numbers of carbon atoms, etc. outside these ranges or different from the individual values, and still obtain the desired results. Any methods, apparatus, and materials similar or equivalent to those described herein, when used for practice or testing the present invention, are within the protection scope of the present application.Notes: The percentages described in the present invention are all weight percentages, unless otherwise indicated. The ratios of the solvate crystals, the eutectic crystals, or the salt-form crystals in the present invention are molar ratios, unless otherwise indicated.Test conditions and detection methods:X-ray powder diffraction test conditions: instrument: Panalytical EMPYREAN (PANalytical, Netherlands); radiation source: Cu-Kα (40 kV, 40 mA).X-ray single-crystal diffraction test conditions: instrument: SXtaLAB Synergy R (Rigaku, Japan); radiation source: Cu target light source, λ = 1.54184 Å; test temperature: 150.0 K; data processing: a CrysAlisPro software package was used to perform analysis and processing.Differential scanning calorimetry analysis test conditions: instrument: TA Discovery 2500 (TA, USA); warming rate: 10 oC / min; nitrogen flow rate: 50 mL / min.Thermogravimetric analysis test conditions: instrument: TA Discovery 55 (TA, USA); warming rate: 10 oC / min; nitrogen flow rate: the nitrogen purge rate at the sample was 60 mL / min, and the nitrogen purge rate at the balance was 40 mL / min.Dynamic vapor sorption / desorption analysis test conditions: instrument: DVS Intrinsic (SMS, UK); humidity change gradient: the testing was performed using a gradient mode, with humidity changes of 50%-95%-0%-50%; for each gradient within the range of 0% to 90%, the humidity change was 10%; the gradient endpoint was determined using dm / dt and was defined as a dm / dt of less than 0.002% lasting for 10 minutes. After the testing was completed, the sample was analyzed by XRPD to determine whether the solid form had changed.Proton nuclear magnetic resonance test conditions: instrument: AV-400 (BRUKER, Germany); solvent: DMSO-d6.Stability test conditions (Examples 40-44): high temperature (60 oC), high humidity (90%), and intense light exposure (4500 Lx) tests were performed according to Appendix XIX C of the Chinese Pharmacopoeia, 2010 Edition, Volume Two.Centrifugal conditions: instrument: DLAB D3024; rotational speed: 10,000 rpm; time: 3 min.Definitions of terms:Regarding the description of hygroscopicity characteristics and the definition of a hygroscopic weight gain (Guidelines for the Hygroscopicity Test of Drugs, General Chapter 9103, the Chinese Pharmacopoeia, 2015 Edition; experimental conditions: 25 oC±1 oC, 80% relative humidity):deliquescence: sufficient water is absorbed to form a liquid;very hygroscopic: the hygroscopic weight gain is not less than 15.0%;hygroscopic: the hygroscopic weight gain is less than 15.0% and is not less than 2.0%;slightly hygroscopic: the hygroscopic weight gain is less than 2.0% and is not less than 0.2%;not hygroscopic or hardly hygroscopic: the hygroscopic weight gain is less than 0.2%.Example A: Preparation of Compound of Formula (I):The structures of the compounds were determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS). The NMR analysis was performed using a Bruker ASCENA-400 nuclear magnetic resonance instrument, with deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD) as solvents and tetramethylsilane (TMS) as an internal standard. The chemical shifts are given in 10-6 (ppm).The reaction monitoring and MS analysis were performed using a Thermofisher ESQ (ESI) mass spectrometer.The HPLC analysis was performed using a Thermo Fisher U3000 DAD high pressure liquid chromatograph (with a GL Sciences ODS-HL HP 3 μm 3.0 × 100 mm chromatography column).The thin-layer chromatography silica gel plates used were Qingdao Haiyang GF254 silica gel plates. The silica gel plates used in the thin-layer chromatography (TLC) analysis were 0.15-0.2 mm silica gel plates, and the plates used in the thin-layer chromatography separation and purification of the products were 0.9-1.0 mm preparative high-performance thin-layer chromatography plates. A Qingdao Haiyang 200-300 mesh silica gel was used as a carrier in the column chromatography. The developing solvent systems used include A: a dichloromethane and methanol system; B: a petroleum ether and ethyl acetate system. The volume ratio of the solvents was adjusted depending on the polarity of the compound. The preparative intermediate-pressure liquid chromatography purification was performed using a biotage isera one preparative liquid chromatography system.All the reaction starting materials are commercially available from manufacturers such as Sun Chemical Technology (Shanghai) Co., Ltd., Shanghai Accela ChemBio Co., Ltd., Nanjing PharmaBlock Sciences Inc., Jiangsu Aikon Biopharmaceutical R&D Co., Ltd., and Shanghai Bide Pharmatech Co., Ltd.6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide <!--[if gte vml 1]><v:shape id="_x0000_i1036" type="#_x0000_t75" style='width:386.25pt; height:157.5pt' o:ole=""><v:imagedata src="tmpusyf2wzl_files / image012.emz" o:title="" / >< / v:shape><![endif]--><!--[if !vml]--><!--[endif]--><!--[if gte mso 9]><xml><o:OLEObject Type="Embed" ProgID="ChemDraw.Document.6.0" ShapeID="_x0000_i1036" DrawAspect="Content" ObjectID="_1800177702">< / o:OLEObject>< / xml><![endif]-->Step 1: 3-Bromo-2-methoxyaniline (212-a, 2.8 g, 13.86 mmol), bis(pinacolato)diboron (5.3 g, 20.79 mmol), Pd(dppf)Cl2 (1.03 g, 1.39 mmol), and potassium acetate (4.08 g, 41.58 mmol) were sequentially added to a dioxane solution. The system was subjected to 3 vaccumization-nitrogen purging cycles, and the mixture was further stirred at 110 °C for 20 hours. TLC monitoring showed that the reaction was complete. The reaction mixture was fully concentrated. Water (40 mL) was added to the reaction mixture, and extraction was performed with ethyl acetate (30 mL × 2). The extract was washed with saturated brine (30 mL × 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (ethyl acetate:petroleum ether = 1:4) to give 2-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (212-b, 2.3 g, 9.23 mmol, 66% yield). MS Calcd: 249.15; MS Found: 250.01 ([M+H]+).Step 2: 2-Methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (212-b, 2.3 g, 9.23 mmol) and Boc anhydride (2.41 g, 11.07 mmol) were added to 10 mL of ethanol solvent, and the mixture was stirred overnight at room temperature. TLC monitoring showed that the reaction was complete. The filtrate was concentrated, and the residue was separated and purified by silica gel column chromatography (ethyl acetate:petroleum ether = 1:4) to give tert-butyl (2-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate (212-c, 2.4 g, 8 mmol, 86% yield). MS Calcd: 348.20; MS Found: 250.16 ([M-100]+).Step 3: tert-Butyl (2-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate (212-c, 370 mg, 1.06 mmol), 2-bromopyrimidine (200 mg, 1.27 mmol), potassium phosphate (521 mg, 2.46 mmol), and Pd(dppf)Cl2 (59 mg, 0.082 mmol) were added to 7 mL of a mixed solution of water and dioxane (6:1). The system was subjected to 3 vaccumization-nitrogen purging cycles, and the mixture was stirred at 105 °C for 10 hours. TLC monitoring showed that the reaction was complete. The reaction mixture was fully concentrated, and the residue was separated and purified by silica gel column chromatography (ethyl acetate:petroleum ether = 1:1) to give tert-butyl (2-methoxy-3-(pyrimidin-2-yl)phenyl)carbamate (212-d, 150 mg, 0.5 mmol, 39% yield). MS Calcd: 300.13; MS Found: 301.12 ([M+H]+).Step 4: tert-Butyl (2-methoxy-3-(pyrimidin-2-yl)phenyl)carbamate (212-d, 150 mg, 0.5 mmol) was dissolved in a dichloromethane solution, and trifluoroacetic acid (421 mg, 3.7 mmol) was then added. The mixture was stirred at room temperature for 5 h. TLC monitoring showed that the reaction was complete. The reaction mixture was fully concentrated, and a saturated sodium bicarbonate solution was added to the residue. Extraction was performed with dichloromethane, and the extract was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography to give the product 2-methoxy-3-(pyrimidin-2-yl)aniline (212-e, 70 mg, 0.35 mmol, 70% yield). MS Calcd: 201.23; MS Found: 202.10 ([M+H]+).Step 5: 2-Methoxy-3-(pyrimidin-2-yl)aniline (212-e, 70 mg, 0.35 mmol) and 4,6-dichloro-N-ethoxynicotinamide (74 mg, 0.32 mmol) were added to 5 mL of anhydrous N,N-dimethylacetamide, and a solution of LiHMDS in tetrahydrofuran (1.28 mL, 1.28 mmol) was added at room temperature. The mixture was stirred at room temperature for 3 hours. TLC monitoring showed that the reaction was complete. The pH was adjusted to 5 using hydrochloric acid (4 N), and extraction was performed with ethyl acetate (20 mL × 3). The organic layers were combined, dried, concentrated, and then purified by silica gel column chromatography (PE:EA = 1:2) to give 6-chloro-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide (212-f, 110 mg, 0.27 mmol, 72% yield). MS Calcd: 399.11; MS Found: 400.11 ([M+H]+).Step 6: 6-Chloro-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide (212-f, 110 mg, 0.27 mmol), 4-amino-2,6-dimethylpyrimidine (44 mg, 0.36 mmol), cesium carbonate (195 mg, 0.6 mmol), XantPhos (25 mg, 0.04 mmol), and Pd2(dba)3 (27 mg, 0.029 mmol) were added to anhydrous dioxane (2 mL), and the system was subjected to 3 vaccumization-nitrogen purging cycles. The mixture was heated to 125 °C, stirred for 10 hours, and filtered under vacuum. The filtrate was concentrated and purified by preparative TLC (MeOH:DCM = 1:20) to give the title compound: 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide (212, 20 mg, 0.04 mmol, 15% yield). MS Calcd: 486.21; MS Found: 487.21 ([M+H]+). 1H NMR (400 MHz, DMSO-d6) δ 11.70 (s, 1H), 10.22 (s, 1H), 10.10 (s, 1H), 8.95 (d, J = 4.8 Hz, 2H), 8.39 (s, 1H), 8.17 (s, 1H), 7.73 (dd, J = 8.0, 1.6 Hz, 1H), 7.51 (t, J = 4.8 Hz, 1H), 7.46 (dd, J = 8.0, 1.6 Hz, 1H), 7.32 (t, J = 8.0 Hz, 1H), 7.09 (s, 1H), 3.96 (q, J = 7.2 Hz, 2H), 3.70 (s, 3H), 2.39 (s, 3H), 2.28 (s, 3H), 1.23 (t, J = 7.2 Hz, 3H). Example 1: Preparation of Methanol Solvated Crystal A of Compound of Formula (I)19.3 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 1.2 mL of methanol was added. The tube was heated at 50 oC until the compound was completely dissolved, and then the solution was quickly transferred to a 25 oC place for cooling crystallization. After 3 hours of crystallization, the solid was collected by centrifugal separation and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 1, and its proton nuclear magnetic resonance spectrum is shown in FIG. 2. FIG. 2 shows that the crystal contains methanol, and that the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to methanol is 1:1.Example 2: Preparation of Hydrate Crystal AA of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide20.6 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 10 mL EP tube, and 10 mL of water was added. The mixture was heated to 50 oC and subjected to suspended stirring for 24 hours, and then the suspension was centrifugally separated. The resulting solid was dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 3, and its proton nuclear magnetic resonance spectrum is shown in FIG. 4. FIG. 4 shows that the crystal does not contain an organic solvent.Example 3: Preparation of Methanol Solvated Crystal AE of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide20.7 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 1.0 mL of methanol was added. The mixture was subjected to suspended stirring at 25 oC for 7 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 5, and its proton nuclear magnetic resonance spectrum is shown in FIG. 6. FIG. 6 shows that the crystal contains methanol, and that the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to methanol is 1:0.4.Example 4: Preparation of Non-Solvate Crystal AH of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide591.4 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 40 mL glass flask, and 3 mL of tetrahydrofuran was added. The mixture was stirred at 25 oC to dissolve the compound. After the solvent was completely volatilized, the resulting solid was heated at 120 oC for about 30 minutes. Subsequently, the resulting solid was dried in vacuo at 80 oC for 18 hours to give a sample. The sample obtained was subjected to XRPD testing, differential scanning calorimetry analysis, thermogravimetric analysis, and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 7, its proton nuclear magnetic resonance spectrum is shown in FIG. 8, its differential scanning calorimetry analysis curve is shown in FIG. 9, and its thermogravimetric analysis curve is shown in FIG. 10. FIG. 8 shows that the crystal does not contain an organic solvent.Example 5: Preparation of Non-Solvate Crystal E of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide602.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 40 mL glass flask, and 21 mL of ethyl acetate was added. The mixture was subjected to suspended stirring at 50 oC for 24 hours, and then the suspension was centrifugally separated. The resulting solid was dried in vacuo at 40 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing, differential scanning calorimetry analysis, thermogravimetric analysis, and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 11, its proton nuclear magnetic resonance spectrum is shown in FIG. 12, its differential scanning calorimetry analysis curve is shown in FIG. 13, and its thermogravimetric analysis curve is shown in FIG. 14. FIG. 12 shows that the crystal does not contain an organic solvent.Example 6: Preparation of Non-Solvate Crystal E Single Crystal of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide20.9 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 2.6 mL of acetonitrile was added. The mixture was heated at 50 oC to dissolve the compound, and then the solution was cooled to 25 oC. A single crystal was picked out from the flaky crystal obtained and subjected to X-ray single-crystal diffraction analysis at 150 K. Its X-ray single-crystal diffraction pattern is shown in FIG. 15, and its unit cell parameters are as follows:crystalline form: triclinic crystal systema = 9.63590(19) Å;b = 10.6920(3) Å;c = 12.4689(2) Å;α = 76.404(2)o;β = 86.6962(16)o;γ = 70.126(2)o;space group: P-1;molecules in each unit cell (Z): 2;unit cell volume: 1173.91 Å3;calculated density: 1.376 g / cm3.Example 7: Preparation of Formic Acid Solvated Crystal F of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide20.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 10 mL of butyl formate was added. The mixture was subjected to suspended stirring at 25 oC for 7 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 16, and its proton nuclear magnetic resonance spectrum is shown in FIG. 17. FIG. 17 shows that the crystal contains formic acid, and that the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to formic acid is 1:1.Example 8: Preparation of Formic Acid Solvation Complex Crystal O of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide20.0 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 2.0 mL of ethyl formate was added. The mixture was heated to 50 oC and subjected to suspended stirring for 24 hours, and then the suspension was centrifugally separated. The resulting solid was dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 18, and its proton nuclear magnetic resonance spectrum is shown in FIG. 19. FIG. 19 shows that the crystal contains formic acid, and that the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to formic acid is 1:1.Example 9: Preparation of Hydrate Crystal T of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide43.6 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 3.0 mL of water was added. The mixture was subjected to suspended stirring at 25 oC for 7 days, and then the suspension was centrifugally separated. The resulting solid was dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 20, and its proton nuclear magnetic resonance spectrum is shown in FIG. 21. FIG. 21 shows that the crystal does not contain an organic solvent.Example 10: Preparation of Hydrate Crystal V of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide46.5 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 0.5 mL of water was added, and 0.5 mL of isopropanol was added. The mixture was subjected to suspended stirring at 25 oC for 7 days, and then the suspension was centrifugally separated. The resulting solid was dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 22, and its proton nuclear magnetic resonance spectrum is shown in FIG. 23. FIG. 23 shows that the crystal does not contain an organic solvent.Example 11: Preparation of Formic Acid Solvation Complex Crystal AF of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide20.1 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 10 mL EP tube, and 3.2 mL of methanol and 6.0 mL of ethyl formate were added at 25 oC to dissolve the compound completely. The solution was then left to stand in an open flask at 25 oC to volatilize. After 7 days, the solution completely volatilized, and a sample was obtained. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 24, and its proton nuclear magnetic resonance spectrum is shown in FIG. 25. FIG. 25 shows that the crystal contains formic acid, an organic solvent, and that the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to formic acid is 1:1. Example 12: Preparation of Hydrate Crystal L of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide21.7 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 10 mL EP tube, and 1.8 mL of acetone was added at 25 oC to dissolve the compound completely. Then 6.0 mL of n-heptane was added dropwise to precipitate a solid, and stirring crystallization was performed at 25 oC for 24 hours. The solid-liquid mixture was then centrifugally separated, and the resulting solid was dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 26, and its proton nuclear magnetic resonance spectrum is shown in FIG. 27. FIG. 27 shows that the crystal does not contain an organic solvent.Example 13: Preparation of Ethanol Solvation Complex Crystal R of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide21.1 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 10 mL EP tube, and 0.6 mL of ethanol was added. The mixture was subjected to suspended stirring at 25 oC for 7 days, and then the suspension was centrifugally separated. The resulting solid was dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 28, and its proton nuclear magnetic resonance spectrum is shown in FIG. 29. FIG. 29 shows that the crystal contains ethanol, and that the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to ethanol is 1:0.3.Example 14: Preparation of Oxalic Acid Eutectic Crystal Type A of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide29.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 0.5 mL of methanol and 5.6 mg of oxalic acid were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 30, and its proton nuclear magnetic resonance spectrum is shown in FIG. 31. FIG. 31 shows that the crystal contains oxalic acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows no significant deviations in chemical shift, suggesting that the crystalline form is a eutectic system, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to oxalic acid is 1:1.Example 15: Preparation of Oxalic Acid Eutectic Crystal Type B of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide29.3 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 1 mL of ethyl acetate and 5.6 mg of oxalic acid were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 40 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 32, and its proton nuclear magnetic resonance spectrum is shown in FIG. 33. FIG. 33 shows that the crystal contains oxalic acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows no significant deviations in chemical shift, suggesting that the crystalline form is a eutectic system, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to oxalic acid is 1:1.Example 16: Preparation of p-Toluenesulfonate Crystal Type A of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide28.6 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 0.5 mL of methanol and 11.8 mg of p-toluenesulfonic acid were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 34, and its proton nuclear magnetic resonance spectrum is shown in FIG. 35. FIG. 35 shows that the crystal contains p-toluenesulfonic acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows significant deviations in chemical shift, suggesting that the crystalline form is a salt-formation crystal, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to p-toluenesulfonic acid is 1:1.Example 17: Preparation of p-Toluenesulfonate Crystal Type B of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide27.8 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 1.0 mL of 4-methyl-2-pentanone and 11.6 mg of p-toluenesulfonic acid were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 36, and its proton nuclear magnetic resonance spectrum is shown in FIG. 37. FIG. 37 shows that the crystal contains p-toluenesulfonic acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows significant deviations in chemical shift, suggesting that the crystalline form is a salt-formation crystal, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to p-toluenesulfonic acid is 1:1.Example 18: Preparation of p-Toluenesulfonate Crystal Type C of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide29.1 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 1.0 mL of ethyl acetate and 11.3 mg of p-toluenesulfonic acid were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 40 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 38, and its proton nuclear magnetic resonance spectrum is shown in FIG. 39. FIG. 39 shows that the crystal contains p-toluenesulfonic acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows significant deviations in chemical shift, suggesting that the crystalline form is a salt-formation crystal, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to p-toluenesulfonic acid is 1:1.Example 19: Preparation of Fumaric Acid Eutectic Crystal Type B of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide29.1 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 1.0 mL of 4-methyl-2-pentanone and 7.1 mg of fumaric acid were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was directly subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 40, and its proton nuclear magnetic resonance spectrum is shown in FIG. 41. FIG. 41 shows that the crystal contains fumaric acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows no significant deviations in chemical shift, suggesting that the crystalline form is a eutectic system, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to fumaric acid is 1:1.Example 20: Preparation of Fumaric Acid Eutectic Crystal Type C of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide29.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 1.0 mL of ethyl acetate and 7.2 mg of fumaric acid were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 40 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 42, and its proton nuclear magnetic resonance spectrum is shown in FIG. 43. FIG. 43 shows that the crystal contains fumaric acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows no significant deviations in chemical shift, suggesting that the crystalline form is a eutectic system, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to fumaric acid is 1:1.Example 21: Preparation of Methanesulfonate Crystal Type A of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide28.7 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 0.5 mL of methanol and 60 μL of a 1 mol / L solution of methanesulfonic acid in ethanol were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 44, and its proton nuclear magnetic resonance spectrum is shown in FIG. 45. FIG. 45 shows that the crystal contains methanesulfonic acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows significant deviations in chemical shift, suggesting that the crystalline form is a salt-formation crystal, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to methanesulfonic acid is 1:1.Example 22: Preparation of Methanesulfonate Crystal Type B of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide29.5 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 1.0 mL of 4-methyl-2-pentanone and 60 μL of a 1 mol / L solution of methanesulfonic acid in ethanol were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 46, and its proton nuclear magnetic resonance spectrum is shown in FIG. 47. FIG. 47 shows that the crystal contains methanesulfonic acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows significant deviations in chemical shift, suggesting that the crystalline form is a salt-formation crystal, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to methanesulfonic acid is 1:1.2.Example 23: Preparation of Methanesulfonate Crystal Type C of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide29.5 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 1.0 mL of ethyl acetate and 60 μL of a 1 mol / L solution of methanesulfonic acid in ethanol were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 40 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 48, and its proton nuclear magnetic resonance spectrum is shown in FIG. 49. FIG. 49 shows that the crystal contains methanesulfonic acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows significant deviations in chemical shift, suggesting that the crystalline form is a salt-formation crystal, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to methanesulfonic acid is 1:1.Example 24: Preparation of Potassium Salt Crystal Type A of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide28.5 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 1.0 mL of 4-methyl-2-pentanone and 3.7 mg of potassium hydroxide were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 50, and its proton nuclear magnetic resonance spectrum is shown in FIG. 51. FIG. 51 shows that a comparison of its proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows significant deviations in chemical shift, suggesting that the crystalline form is a salt-formation crystal.Example 25: Preparation of Maleate Crystal Type A of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide28.8 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 7.0 mg of maleic acid and 1.0 mL of 4-methyl-2-pentanone were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 52, and its proton nuclear magnetic resonance spectrum is shown in FIG. 53. FIG. 53 shows that a comparison of its proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows significant deviations in chemical shift, suggesting that the crystalline form is a salt-formation crystal, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to maleic acid is 1:1.Example 26: Preparation of Maleate Crystal Type B of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide29.3 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 7.0 mg of maleic acid and 2.0 mL of ethyl acetate were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 54, and its proton nuclear magnetic resonance spectrum is shown in FIG. 55. FIG. 55 shows that a comparison of its proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows significant deviations in chemical shift, suggesting that the crystalline form is a salt-formation crystal, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to maleic acid is 1:1.Example 27: Preparation of Sodium Salt Crystal Type B of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide29.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 2.6 mg of sodium hydroxide and 1.0 mL of ethyl acetate were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 56, and its proton nuclear magnetic resonance spectrum is shown in FIG. 57. FIG. 57 shows that a comparison of its proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows significant deviations in chemical shift, suggesting that the crystalline form is a salt-formation crystal.Example 28: Preparation of Citrate Salt Eutectic Type A of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide28.8 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 11.6 mg of citric acid and 1.0 mL of 4-methyl-2-pentanone were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 58, and its proton nuclear magnetic resonance spectrum is shown in FIG. 59. FIG. 59 shows that a comparison of its proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows no significant deviations in chemical shift, suggesting that no salt has formed, in which 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide:citric acid = 1:1.Example 29: Preparation of Malic Acid Eutectic Crystal Type A of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide29.0 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 1.0 mL of 4-methyl-2-pentanone and 8.1 mg of malic acid were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 60, and its proton nuclear magnetic resonance spectrum is shown in FIG. 61. FIG. 61 shows that the crystal contains malic acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form A shows no significant deviations in chemical shift, suggesting that the crystalline form is a eutectic system, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to malic acid is 1:1.Example 30: Preparation of Hydrochloride Type A of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide29.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 1.0 mL of 4-methyl-2-pentanone and 60 μL of a 1 mol / L solution of hydrochloric acid in ethanol were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 62, and its proton nuclear magnetic resonance spectrum is shown in FIG. 63. FIG. 63 shows that the crystal contains hydrochloric acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows significant deviations in chemical shift, suggesting that the crystalline form is a hydrochloride crystal, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to hydrochloric acid is 1:1.Example 31: Preparation of Hydrochloride Type B of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide29.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, and 1.0 mL of ethyl acetate and 60 μL of a 1 mol / L solution of hydrochloric acid in ethanol were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 40 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 64, and its proton nuclear magnetic resonance spectrum is shown in FIG. 65. FIG. 65 shows that its proton nuclear magnetic resonance spectrum indicates that the crystal contains hydrochloric acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows significant deviations in chemical shift, suggesting that the crystalline form is a salt-formation crystal, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to hydrochloric acid is 1:1.Example 32: Preparation of Glycolic Acid Eutectic Crystal Type A of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide28.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 10 mL EP tube, and 4.8 μL of glycolic acid and 0.5 mL of methanol were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was directly subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 66, and its proton nuclear magnetic resonance spectrum is shown in FIG. 67. FIG. 67 shows that its proton nuclear magnetic resonance spectrum indicates that the crystal contains glycolic acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows no significant deviations in chemical shift, suggesting that the crystalline form is a eutectic system, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to glycolic acid is 1:1.Example 33: Preparation of Glycolic Acid Eutectic Crystal Type B of 6-(((2,6-Dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide28.3 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 10 mL EP tube, and 4.9 μL of glycolic acid and 1.0 mL of 4-methyl-2-pentanone were added. The mixture was subjected to suspended stirring at 25 oC for 2 days, and then the suspension was centrifugally separated. The solid was collected and dried in vacuo at 25 oC for 24 hours to give a sample. The sample obtained was subjected to XRPD testing and proton nuclear magnetic resonance analysis. Its X-ray powder diffraction pattern is shown in FIG. 68, and its proton nuclear magnetic resonance spectrum is shown in FIG. 69. FIG. 69 shows that the crystal contains glycolic acid, and a comparison of the proton nuclear magnetic resonance spectrum with the proton nuclear magnetic resonance spectrum of the crystalline form E shows no significant deviations in chemical shift, suggesting that the crystalline form is a eutectic system, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to glycolic acid is 1:1.Example 34: Thermodynamic Stability of Non-Solvated Crystalline Form EA certain amount, by mass, of the methanol solvated crystal A was taken, and 1.0 mL of acetonitrile or 1.0 mL of methyl tert-butyl ether (MTBE) was added. The mixture was stirred at a different temperature to form a saturated solution, and then an equal amount of the non-solvated crystalline form E and the non-solvated crystalline form AH was added to the saturated solution. The mixture was subjected to suspended stirring at the particular temperature selected for 6 days, and the solid in the mixture was obtained by centrifugation. The crystalline form of the solid was determined again by XRPD. The results are shown in Table 1, and a comparison of the XRPD patterns after stirring is shown in FIG. 70.Table 1Experiment No.Amount of crystalline form E (mg)Amount of crystalline form AH (mg)SolventVolume (mL)Temperature (oC)Result15.65.8Acetonitrile1.010Crystalline form E25.55.5Acetonitrile1.0Room temperatureCrystalline form E35.35.0Acetonitrile1.060Crystalline form E45.95.1Methyl tert-butyl ether1.010Crystalline form E55.36.0Methyl tert-butyl ether1.0Room temperatureCrystalline form E65.45.3Methyl tert-butyl ether1.045Crystalline form EThe results show that the crystalline form E is more stable than the crystalline form AH under the test conditions.Example 35: Hygroscopicity of Non-Solvated Crystalline Form E15-20 mg of the non-solvated crystalline form E of the present invention was weighed out, and its hygroscopicity was measured using a dynamic vapor sorption / desorption (DVS) instrument. The testing was performed using a gradient mode. Under the conditions of humidity changes of 50%-95%-0%-50%, one cycle was finished. For each gradient within the range of 0% to 90%, the humidity change was 10%. The gradient endpoint was determined using dm / dt and was defined as a dm / dt of less than 0.002% lasting for 10 minutes. The change in mass at each humidity was recorded, and the corresponding changes in mass are shown in FIG. 71. After the testing was completed, the sample was subjected to XRPD analysis. A comparison of the XRPD patterns is shown in FIG. 72.As can be seen from the DVS experiment, the crystalline form E is not hygroscopic. The XRPD results show that the non-solvated crystalline form E did not transition to another crystalline form before or after the DVS testing.Example 36: Hygroscopicity of Non-Solvated Crystalline Form AH15-20 mg of the non-solvated crystalline form AH of the present invention was weighed out, and its hygroscopicity was measured using a dynamic vapor sorption / desorption (DVS) instrument. The testing was performed using a gradient mode. Under the conditions of humidity changes of 50%-95%-0%-50%, one cycle was finished. For each gradient within the range of 0% to 90%, the humidity change was 10%. The gradient endpoint was determined using dm / dt and was defined as a dm / dt of less than 0.002% lasting for 10 minutes. The change in mass at each humidity was recorded, and the corresponding changes in mass are shown in FIG. 73. After the testing was completed, the sample was subjected to XRPD analysis. A comparison of the XRPD patterns is shown in FIG. 74.As can be seen from the DVS experiment, the crystalline form AH is hygroscopic. The XRPD results show that the non-solvated crystalline form AH did not transition to another crystalline form before or after the DVS testing.Example 37: Hygroscopicity of Maleate Crystalline Form Type A of Compound of Formula (I)15-20 mg of the maleate crystalline form Type A of the compound of formula (I) was weighed out, and its hygroscopicity was measured using a dynamic vapor sorption / desorption (DVS) instrument. The testing was performed using a gradient mode. Under the conditions of humidity changes of 50%-95%-0%-50%, one cycle was finished. For each gradient within the range of 0% to 90%, the humidity change was 10%. The gradient endpoint was determined using dm / dt and was defined as a dm / dt of less than 0.002% lasting for 10 minutes. The change in mass at each humidity was recorded, and the corresponding changes in mass are shown in FIG. 75. After the testing was completed, the sample was subjected to XRPD analysis. A comparison of the XRPD patterns is shown in FIG. 76.As can be seen from the DVS experiment, the maleate crystalline form Type A of the compound of formula (I) is very hygroscopic. The XRPD results show that the maleate crystalline form Type A of the compound of formula (I) did not transition to another crystalline form before or after the DVS testing.Example 38: Hygroscopicity of Citric Acid Eutectic Crystalline Form Type A of Compound of Formula (I)15-20 mg of the citric acid eutectic crystalline form Type A of the compound of formula (I) was weighed out, and its hygroscopicity was measured using a dynamic vapor sorption / desorption (DVS) instrument. The testing was performed using a gradient mode. Under the conditions of humidity changes of 50%-95%-0%-50%, one cycle was finished. For each gradient within the range of 0% to 90%, the humidity change was 10%. The gradient endpoint was determined using dm / dt and was defined as a dm / dt of less than 0.002% lasting for 10 minutes. The change in mass at each humidity was recorded, and the corresponding changes in mass are shown in FIG. 77. After the testing was completed, the sample was subjected to XRPD analysis. A comparison of the XRPD patterns is shown in FIG. 78.As can be seen from the DVS experiment, the citric acid eutectic crystalline form Type A of the compound of formula (I) is hardly hygroscopic. The XRPD results show that the citric acid eutectic crystalline form Type A of the compound of formula (I) did not transition to another crystalline form before or after the DVS testing.Example 39: Hygroscopicity of Malic Acid Eutectic Crystalline Form Type A of Compound of Formula (I)15-20 mg of the malic acid eutectic crystalline form Type A of the compound of formula (I) was weighed out, and its hygroscopicity was measured using a dynamic vapor sorption / desorption (DVS) instrument. The testing was performed using a gradient mode. Under the conditions of humidity changes of 50%-95%-0%-50%, one cycle was finished. For each gradient within the range of 0% to 90%, the humidity change was 10%. The gradient endpoint was determined using dm / dt and was defined as a dm / dt of less than 0.002% lasting for 10 minutes. The change in mass at each humidity was recorded, and the corresponding changes in mass are shown in FIG. 79. After the testing was completed, the sample was subjected to XRPD analysis. A comparison of the XRPD patterns is shown in FIG. 80.As can be seen from the DVS experiment, the malic acid eutectic crystalline form Type A of the compound of formula (I) is slightly hygroscopic. The XRPD results show that the malic acid eutectic crystalline form Type A of the compound of formula (I) did not transition to another crystalline form before or after the DVS testing.Example 40: Stability of Non-Solvated Crystalline Form ESamples of about 15 mg of the non-solvated crystalline form E of the present invention were weighed out and placed in weighing bottles, and the bottles were left to stand open under high temperature (60 °C), high humidity (25 °C / 92.5% RH), light exposure (25 °C / 4500 Lux), accelerated (40 °C / 75% RH), and room temperature (25 oC / 60% RH) conditions, respectively. Samples were taken at particular time points for XRPD characterization. The results are shown in Table 2, and a comparison of the XRPD patterns is shown in FIG. 81.Table 2 Starting crystalline formStanding conditionsStanding time15-day result30-day result90-day resultCrystalline form EHigh temperature 60 oCThe crystalline form did not changeThe crystalline form did not changeThe crystalline form did not changeCrystalline form EHigh humidity 25 oC / 92.5% RHThe crystalline form did not changeThe crystalline form did not changeThe crystalline form did not changeCrystalline form ELight exposure 25 oC / 4500 LuxNew peaks appear at 7.68° and 13.04°New peaks appear at 7.68° and 13.04°The crystalline form did not changeCrystalline form EAccelerated 40 oC / 75% RHThe crystalline form did not changeThe crystalline form did not changeThe crystalline form did not changeCrystalline form E25 oC / 60%RHThe crystalline form did not changeThe crystalline form did not changeThe crystalline form did not changeAccording to the above experimental results, the non-solvated crystalline form E remained stable under high temperature, high humidity, accelerated, and room temperature conditions, indicating that it is highly stable.Example 41: Stability of Non-Solvated Crystalline Form AHSamples of about 15 mg of the non-solvated crystalline form AH of the present invention were weighed out and placed in weighing bottles, and the bottles were left to stand open under high temperature (60 °C), high humidity (25 °C / 92.5% RH), light exposure (25 °C / 4500 Lux), accelerated (40 °C / 75% RH), and room temperature (25 oC / 60% RH) conditions, respectively. Samples were taken at particular time points for XRPD characterization. The results are shown in Table 3, and a comparison of the XRPD patterns is shown in FIG. 82.Table 3Starting crystalline formStanding conditionsStanding time15-day result30-day result90-day resultCrystalline form AHHigh temperature 60 oCThe crystalline form did not changeThe crystalline form did not changeThe crystalline form did not changeCrystalline form AHHigh humidity 25 oC / 92.5% RHThe crystalline form did not changeThe crystalline form did not changeThe crystalline form did not changeCrystalline form AHLight exposure 25 oC / 4500 LuxThe crystalline form did not changeThe crystalline form did not changeThe crystalline form did not changeCrystalline form AHAccelerated 40 oC / 75% RHThe crystalline form did not changeThe crystalline form did not changeThe crystalline form did not changeCrystalline form AH25 oC / 60%RHThe crystalline form did not changeThe crystalline form did not changeThe crystalline form did not changeAccording to the above experimental results, the non-solvated crystalline form AH remained stable under high temperature, high humidity, light exposure, accelerated, and room temperature conditions, indicating that it is highly stable.Example 42: Stability of Maleate Crystalline Form Type A of Compound of Formula (I)Samples of about 15 mg of the maleate crystalline form Type A of the compound of formula (I) of the present invention were weighed out and placed in weighing bottles, and the bottles were left to stand open under high temperature (60 °C), high humidity (25 °C / 92.5% RH), light exposure (25 °C / 4500 Lux), accelerated (40 °C / 75% RH), and room temperature (25 oC / 60% RH) conditions, respectively. Samples were taken at particular time points for XRPD characterization. The results are shown in Table 4, and a comparison of the XRPD patterns is shown in FIG. 83.Table 4Starting crystalline formStanding conditionsStanding timeResultMaleate crystalline form Type AHigh temperature 60 oC7 daysThe crystalline form did not changeMaleate crystalline form Type AHigh humidity 25 oC / 92.5% RH7 daysThe crystalline form did not changeMaleate crystalline form Type ALight exposure 25 oC / 4500 Lux7 daysThe crystalline form did not change, and the sample’s color changed from white to yellowMaleate crystalline form Type AAccelerated 40 oC / 75% RH7 daysThe crystalline form did not changeMaleate crystalline form Type A25 oC / 60%RH7 daysThe crystalline form did not changeAccording to the above experimental results, the maleate crystalline form Type A remained stable under high temperature, high humidity, accelerated, and room temperature conditions, indicating that it is highly stable.Example 43: Stability of Citric Acid Eutectic Crystalline Form Type A of Compound of Formula (I)Samples of about 15 mg of the citrate eutectic crystalline form Type A of the compound of formula (I) of the present invention were weighed out and placed in weighing bottles, and the bottles were left to stand open under high temperature (60 °C), high humidity (25 °C / 92.5% RH), light exposure (25 °C / 4500 Lux), accelerated (40 °C / 75% RH), and room temperature (25 oC / 60% RH) conditions, respectively. Samples were taken at particular time points for XRPD characterization. The results are shown in Table 5, and a comparison of the XRPD patterns is shown in FIG. 84.Table 5Starting crystalline formStanding conditionsStanding timeResultCitrate eutectic crystalline form Type AHigh temperature 60 oC7 daysThe crystalline form did not changeCitrate eutectic crystalline form Type AHigh humidity 25 oC / 92.5% RH7 daysThe crystalline form did not changeCitrate eutectic crystalline form Type ALight exposure 25 oC / 4500 Lux7 daysThe crystalline form did not change, and the sample’s color changed from white to yellowCitrate eutectic crystalline form Type AAccelerated 40 oC / 75% RH7 daysThe crystalline form did not changeCitrate eutectic crystalline form Type A25 oC / 60%RH7 daysThe crystalline form did not changeAccording to the above experimental results, the citrate eutectic crystalline form Type A remained stable under high temperature, high humidity, accelerated, and room temperature conditions, indicating that it is highly stable.Example 44: Stability of Malic Acid Eutectic Crystalline Form Type A of Compound of Formula (I)Samples of about 15 mg of the malate eutectic crystalline form Type A of the compound of formula (I) of the present invention were weighed out and placed in weighing bottles, and the bottles were left to stand open under high temperature (60 °C), high humidity (25 °C / 92.5% RH), light exposure (25 °C / 4500 Lux), accelerated (40 °C / 75% RH), and room temperature (25 oC / 60% RH) conditions, respectively. Samples were taken at particular time points for XRPD characterization. The results are shown in Table 6, and a comparison of the XRPD patterns is shown in FIG. 85.Table 6Starting crystalline formStanding conditionsStanding timeResultMalate eutectic crystalline form Type AHigh temperature 60 oC7 daysThe crystalline form did not changeMalate eutectic crystalline form Type AHigh humidity 25 oC / 92.5% RH7 daysThe crystalline form did not changeMalate eutectic crystalline form Type ALight exposure 25 oC / 4500 Lux7 daysThe crystalline form did not change, and the sample’s color changed from white to yellowMalate eutectic crystalline form Type AAccelerated 40 oC / 75% RH7 daysThe crystalline form did not changeMalate eutectic crystalline form Type A25 oC / 60%RH7 daysThe crystalline form did not change According to the above experimental results, the malate eutectic crystalline form Type A remained stable under high temperature, high humidity, accelerated, and room temperature conditions, indicating that it is highly stable. 

Claims

A non-solvated crystal, hydrate crystal, solvated crystal, eutectic crystal, or salt-form crystal of the compound represented by formula (I), wherein: (I); the non-solvated crystal is selected from:a non-solvated crystal AH, wherein an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.65o, 11.26o, 11.43o, 15.07o, 15.32o, 19.07o, 20.12o, and 20.78o; anda non-solvated crystal E, wherein an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.19o, 9.59o, 14.46o, 18.15o, 20.41o, 23.44o, 23.67o, 24.01o, 24.34o, and 24.60o;the hydrate crystal is selected from:a hydrate crystal AA, wherein an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.85o, 10.35o, 12.74o, 14.95o, 17.94o, 18.05o, 19.01o, 20.90o, and 27.26o;a hydrate crystal T, wherein an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.31o, 6.09o, 6.82o, 11.05o, 18.49o, 19.74o, 24.32o, and 26.78o;a hydrate crystal V, wherein an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.34o, 7.48o, 7.95o, 10.27o, 12.97o, 17.90o, 20.71o, and 23.98o; anda hydrate crystal L, wherein an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.69o, 8.02o, 9.93o, 14.23o, 16.13o, 16.29o, 18.13o, 19.18o, and 24.32o;the solvated crystal is selected from: a methanol solvate crystal A, wherein a ratio of the compound represented by formula (I) to methanol is 1:1; an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.56o, 9.16o, 9.34o, 12.91o, 13.78o, 14.66o, 15.25o, 18.52o, and 23.12o;a methanol solvated crystal AE, wherein a ratio of the compound represented by formula (I) to methanol is 1:0.4; an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 9.08o, 9.63o, 13.11o, 13.70o, 14.80o, 15.29o, 17.88o, 18.78o, 22.94o, and 23.46o;a formic acid solvated crystal F, wherein a ratio of the compound represented by formula (I) to formic acid is 1:1, and an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.96o, 5.30o, 7.25o, 8.44o, 12.14o, 15.04o, 15.83o, 19.47o, and 20.11o;a formic acid solvated crystal O, wherein a ratio of the compound represented by formula (I) to formic acid is 1:1, and an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.30o, 10.68o, 11.72o, 15.25o, 16.09o, 17.99o, 20.50o, 22.30o, 25.78o, and 26.57o;a formic acid solvated crystal AF, wherein a ratio of the compound represented by formula (I) to formic acid is 1:1, and an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.19o, 7.48o, 8.32o, 12.49o, 13.46o, and 14.76o; andan ethanol solvated crystal R, wherein a ratio of the compound represented by formula (I) to ethanol is 1:0.3, and an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 8.37o, 12.51o, 16.14o, 17.56o, 17.69o, 18.36o, 18.68o, 19.45o, 21.71o, 23.01o, and 24.14o;the eutectic crystal is selected from:an oxalic acid eutectic crystal Type A, wherein a ratio of the compound of formula (I) to oxalic acid is 1:1; an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.07o, 11.01o, 12.23o, 12.80o, 14.28o, 16.93o, and 21.76o;an oxalic acid eutectic crystal Type B, wherein a ratio of the compound of formula (I) to oxalic acid is 1:1; an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.01o, 8.19o, 11.55o, 12.34o, 13.79o, 17.36o, 18.14o, 20.56o, 23.27o, 23.94o, and 25.24o;a fumaric acid eutectic crystal Type B, wherein a ratio of the compound of formula (I) to fumaric acid is 1:1, and an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.18o, 6.43o, 10.93o, 11.46o, 12.39o, 15.96o, 16.22o, 19.28o, and 22.09o;a fumaric acid eutectic crystal Type C, wherein a ratio of the compound of formula (I) to fumaric acid is 1:1, and an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.14o, 7.49o, 10.87o, 12.17o, 17.38o, 19.81o, 20.63o, 21.58o, 23.27o, 24.38o, and 25.39o;a citric acid eutectic crystal Type A, wherein a ratio of the compound of formula (I) to citric acid is 1:1, and an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.56o, 6.52o, 9.85o, 14.27o, 14.62o, 16.60o, 17.73o, 19.71o, 19.86o, 24.36o, and 26.42o;a malic acid eutectic crystal Type A, wherein a ratio of the compound of formula (I) to malic acid is 1:1, and an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.14o, 8.77o, 8.99o, 9.90o, 11.59o, 11.84o, 17.27o, 19.91o, 20.22o, 21.09o, 23.74o, and 25.22o;a glycolic acid eutectic crystal Type A, wherein a ratio of the compound of formula (I) to ethanol is 1:1, and an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.61o, 6.83o, 8.27o, 11.25o, 13.73o, 14.63o, 16.94o, 19.79o, and 23.23o; anda glycolic acid eutectic crystal Type B, wherein a ratio of the compound of formula (I) to ethanol is 1:1, and an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.44o, 6.70o, 8.29o, 10.96o, 13.50o, 14.25o, 16.48o, 20.83o, and 25.06o;the salt-form crystal is selected from:a p-toluenesulfonate crystal Type A, wherein a ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1:1; an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.41o, 9.57o, 9.92o, 16.06o, 16.94o, 19.70o, 20.44o, 22.07o, and 26.24o;a p-toluenesulfonate crystal Type B, wherein a ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1:1; an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.35o, 6.93o, 7.63o, 14.59o, 16.79o, and 20.79o;a p-toluenesulfonate crystal Type C, wherein a ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1:1; an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.19o, 6.87o, 10.06o, 13.79o, 16.62o, 16.93o, 20.44o, 24.53o, and 26.12o;a methanesulfonate crystal Type A, wherein a ratio of the compound represented by formula (I) to methanesulfonic acid is 1:1; an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 8.09o, 9.60o, 11.06o, 12.57o, 14.33o, 14.55o, 16.93o, 19.32o, 19.64o, 20.19o, 20.31o, 21.05o, and 26.42o;a methanesulfonate crystal Type B, wherein a ratio of the compound represented by formula (I) to methanesulfonic acid is 1:1.2; an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.74o, 5.89o, 11.53o, 11.93o, 12.47o, 12.90o, 14.06o, 15.01o, 17.14o, and 25.52o;a methanesulfonate crystal Type C, wherein a ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1:1; an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.32o, 8.45o, 11.84o, 17.01o, 18.49o, 21.30o, and 22.98o;a potassium salt crystal Type A, which has the structure ; an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.74o, 6.68o, 7.96o, 13.54o, 14.04o, 17.78o, 20.14o, and 23.29o;a maleate crystal Type A, wherein a ratio of the compound represented by formula (I) to maleic acid is 1:1, and an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.26o, 4.76o, 7.08o, 7.96o, 8.54o, 9.53o, 10.18o, 10.93o, 14.34o, 15.03o, 15.99o, and 20.50o;a maleate crystal Type B, wherein a ratio of the compound represented by formula (I) to maleic acid is 1:1, and an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.34o, 4.79o, 5.27o, 7.20o, 7.86o, 10.22o, 10.56o, 11.08o, 14.73o, 15.20o, 16.14o, and 20.50o;a sodium salt crystal Type B, which has the structure ; an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.01o, 6.61o, 7.94o, 11.88o, 12.48o, 13.10o, 13.70o, 18.31o, 19.98o, 21.19o, 22.35o, 25.36o, and 26.27o;a hydrochloride crystal Type A, wherein a ratio of the compound represented by formula (I) to hydrochloric acid is 1:1, and an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.90o, 7.42o, 7.74o, 10.96o, 14.07o, 14.96o, 18.01o, 25.14o, and 26.42o; anda hydrochloride crystal Type B, wherein a ratio of the compound represented by formula (I) to hydrochloric acid is 1:1, and an X-ray powder diffraction pattern of the crystal has characteristic diffraction peaks at the following 2θ angles (±0.2o): 6.48o, 7.20o, 7.90o, 14.16o, 14.48o, 15.68o, 17.31o, 21.76o, and 26.53oThe non-solvated crystal, hydrate crystal, solvated crystal, eutectic crystal, or salt-form crystal according to claim 1, wherein the X-ray powder diffraction pattern of the non-solvated crystal AH of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.65o, 11.26o, 11.43o, 15.07o, 15.32o, 16.60o, 19.07o, 20.12o, 20.78o, and 23.02o; orthe X-ray powder diffraction pattern of the non-solvated crystal AH of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.65o, 9.47o, 11.26o, 11.43o, 15.07o, 15.32o, 16.31o, 16.60o, 19.07o, 20.12o, 20.78o, 23.02o, and 25.77o; orthe X-ray powder diffraction pattern of the non-solvated crystal AH of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.65o, 8.36o, 9.47o, 9.80o, 11.26o, 11.43o, 11.55o, 11.80o, 12.95o, 13.64o, 14.34o, 14.74o, 15.07o, 15.32o, 15.91o, 16.31o, 16.60o, 16.87o, 18.72o, 19.07o, 19.73o, 20.12o, 20.78o, 21.30o, 21.45o, 21.95o, 22.31o, 23.02o, 23.30o, 23.67o, 23.84o, 24.65o, 25.77o, 26.57o, 26.90o, 28.29o, 28.85o, and 29.54oThe non-solvated crystal, hydrate crystal, solvated crystal, eutectic crystal, or salt-form crystal according to claim 1, wherein the X-ray powder diffraction pattern of the non-solvated crystal AH of the compound represented by formula (I) is shown in FIG. 7; orthe X-ray powder diffraction pattern of the non-solvated crystal E of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.19o, 9.59o, 13.64o, 14.46o, 18.15o, 19.19o, 20.41o, 23.44o, 23.67o, 24.01o, 24.34o, and 24.60o; orthe X-ray powder diffraction pattern of the non-solvated crystal E of the compound represented by formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.19o, 8.93o, 9.59o, 12.72o, 13.64o, 14.46o, 18.15o, 19.19o, 19.96o, 20.41o, 23.44o, 23.67o, 24.01o, 24.34o, 24.60o, and 28.60o; orthe X-ray powder diffraction pattern of the non-solvated crystal E of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.19o, 8.93o, 9.59o, 10.14o, 10.52o, 11.74o, 12.31o, 12.72o, 13.64o, 14.46o, 15.33o, 15.85o, 16.62o, 17.02o, 18.03o, 18.15o, 18.72o, 19.19o, 19.36o, 19.96o, 20.41o, 20.90o, 23.44o, 23.67o, 24.01o, 24.34o, 24.60o, 25.69o, 26.66o, 28.60o, 29.19o, and 32.08oThe non-solvated crystal, hydrate crystal, solvated crystal, eutectic crystal, or salt-form crystal according to claim 1, wherein the X-ray powder diffraction pattern of the non-solvated crystal E of the compound represented by formula (I) is shown in FIG. 11; orthe X-ray powder diffraction pattern of the hydrate crystal AA of the compound represented by formula (I) is shown in FIG. 3; orthe X-ray powder diffraction pattern of the hydrate crystal T of the compound represented by formula (I) is shown in FIG. 20; orthe X-ray powder diffraction pattern of the hydrate crystal V of the compound of formula (I) is shown in FIG. 22; orthe X-ray powder diffraction pattern of the hydrate crystal L of the compound of formula (I) is shown in FIG. 26; orthe X-ray powder diffraction pattern of the methanol solvate crystal A of the compound represented by formula (I) is shown in FIG. 1; orthe X-ray powder diffraction pattern of the methanol solvate crystal AE of the compound represented by formula (I) is shown in FIG. 5; orthe X-ray powder diffraction pattern of the formic acid solvated crystal F of the compound represented by formula (I) is shown in FIG. 16; orthe X-ray powder diffraction pattern of the formic acid solvated crystal O of the compound represented by formula (I) is shown in FIG. 18; orthe X-ray powder diffraction pattern of the formic acid solvated crystal AF of the compound represented by formula (I) is shown in FIG. 24; orthe X-ray powder diffraction pattern of the ethanol solvate crystal R of the compound represented by formula (I) is shown in FIG. 28; orthe X-ray powder diffraction pattern of the oxalic acid eutectic crystal Type A of the compound of formula (I) is shown in FIG. 30; orthe X-ray powder diffraction pattern of the oxalic acid eutectic crystal Type B of the compound of formula (I) is shown in FIG. 32; orthe X-ray powder diffraction pattern of the fumaric acid eutectic crystal Type B of the compound of formula (I) is shown in FIG. 40; orthe X-ray powder diffraction pattern of the fumaric acid eutectic crystal Type C is shown in FIG. 42The non-solvated crystal, hydrate crystal, solvated crystal, eutectic crystal, or salt-form crystal according to claim 1, wherein the X-ray powder diffraction pattern of the citric acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.56o, 6.52o, 9.85o, 13.20o, 13.46o, 14.27o, 14.62o, 15.78o, 16.60o, 17.73o, 19.71o, 19.86o, 24.36o, 25.16o, and 26.42o; orthe X-ray powder diffraction pattern of the citric acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.56o, 6.52o, 7.10o, 9.85o, 13.20o, 13.46o, 14.27o, 14.62o, 15.41o, 15.78o, 16.29o, 16.60o, 17.73o, 19.31o, 19.71o, 19.86o, 23.15o, 24.36o, 25.16o, and 26.42o; orthe X-ray powder diffraction pattern of the citric acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 5.56o, 6.52o, 7.10o, 9.85o, 11.00o, 12.76o, 13.20o, 13.46o, 14.27o, 14.62o, 15.41o, 15.78o, 16.29o, 16.60o, 17.73o, 19.31o, 19.71o, 19.86o, 23.15o, 23.51o, 24.36o, 25.16o, 25.56o, 25.70o, 26.42o, 27.08o, 27.53o, 27.74o, 28.08o, and 32.03o; orthe X-ray powder diffraction pattern of the citric acid eutectic crystal Type A of the compound of formula (I) is shown in FIG. 58; orthe X-ray powder diffraction pattern of the malic acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.14o, 8.77o, 8.99o, 9.90o, 11.59o, 11.84o, 17.27o, 18.02o, 19.21o, 19.91o, 20.22o, 21.09o, 22.98o, 23.74o, 24.42o, and 25.22o; orthe X-ray powder diffraction pattern of the malic acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.14o, 8.77o, 8.99o, 9.90o, 11.59o, 11.84o, 13.90o, 14.72o, 15.83o, 17.27o, 18.02o, 19.21o, 19.91o, 20.22o, 21.09o, 22.98o, 23.74o, 24.42o, and 25.22o; orthe X-ray powder diffraction pattern of the malic acid eutectic crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 7.14o, 8.77o, 8.99o, 9.90o, 11.59o, 11.84o, 13.90o, 14.72o, 15.83o, 17.27o, 18.02o, 18.49o, 19.21o, 19.91o, 20.22o, 20.49o, 21.09o, 22.32o, 22.98o, 23.74o, 24.42o, 25.22o, 25.58o, 26.30o, 27.04o, 27.86o, 28.46o, 29.20o, 29.84o, 31.18o, 31.42o, 34.27o, and 34.82oThe non-solvated crystal, hydrate crystal, solvated crystal, eutectic crystal, or salt-form crystal according to claim 1, wherein the X-ray powder diffraction pattern of the malic acid eutectic crystal Type A of the compound of formula (I) is shown in FIG. 60; orthe X-ray powder diffraction pattern of the glycolic acid eutectic crystal Type A of the compound of formula (I) is shown in FIG. 66; orthe X-ray powder diffraction pattern of the glycolic acid eutectic crystal Type B of the compound of formula (I) is shown in FIG. 68; orthe X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type A of the compound of formula (I) is shown in FIG. 34; orthe X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type B of the compound of formula (I) is shown in FIG. 36; orthe X-ray powder diffraction pattern of the p-toluenesulfonate crystal Type C of the compound of formula (I) is shown in FIG. 38; orthe X-ray powder diffraction pattern of the methanesulfonate crystal Type A of the compound of formula (I) is shown in FIG. 44; orthe X-ray powder diffraction pattern of the methanesulfonate crystal Type B of the compound of formula (I) is shown in FIG. 46; orthe X-ray powder diffraction pattern of the methanesulfonate crystal Type C of the compound of formula (I) is shown in FIG. 48; orthe X-ray powder diffraction pattern of the potassium salt crystal Type A of the compound of formula (I) is shown in FIG. 50The non-solvated crystal, hydrate crystal, solvated crystal, eutectic crystal, or salt-form crystal according to claim 1, wherein the X-ray powder diffraction pattern of the maleate crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.26o, 4.76o, 7.08o, 7.96o, 8.54o, 9.53o, 10.18o, 10.93o, 13.89o, 14.34o, 15.03o, 15.99o, 20.50o, 21.49o, and 24.03o; orthe X-ray powder diffraction pattern of the maleate crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.26o, 4.76o, 7.08o, 7.96o, 8.54o, 9.53o, 10.18o, 10.93o, 12.41o, 13.89o, 14.34o, 15.03o, 15.99o, 17.93o, 20.50o, 21.49o, 23.55o, and 24.03o; orthe X-ray powder diffraction pattern of the maleate crystal Type A of the compound of formula (I) has characteristic diffraction peaks at the following 2θ angles (±0.2o): 4.26o, 4.76o, 7.08o, 7.96o, 8.54o, 9.53o, 10.18o, 10.93o, 12.41o, 13.89o, 14.34o, 15.03o, 15.99o, 17.93o, 20.50o, 21.49o, 21.97o, 23.55o, 24.03o, 25.19o, 25.57o, and 26.00oThe non-solvated crystal, hydrate crystal, solvated crystal, eutectic crystal, or salt-form crystal according to claim 1, wherein the X-ray powder diffraction pattern of the maleate crystal Type A of the compound of formula (I) is shown in FIG. 52; orthe X-ray powder diffraction pattern of the maleate crystal Type B of the compound of formula (I) is shown in FIG. 54; orthe X-ray powder diffraction pattern of the sodium salt crystal Type B of the compound of formula (I) is shown in FIG. 56; orthe X-ray powder diffraction pattern of the hydrochloride crystal Type A of the compound of formula (I) is shown in FIG. 62; orthe X-ray powder diffraction pattern of the hydrochloride crystal Type B of the compound of formula (I) is shown in FIG. 64A non-solvated crystal E of the compound represented by formula (I), wherein a crystalline form of the crystal is a triclinic system with the following unit cell parameter values: a = 9.63590(19) Å; b = 10.6920(3) Å; c = 12.4689(2) Å; α = 76.404(2)o; β = 86.6962(16)o; γ = 70.126(2)o; space group: P-1; molecules in each unit cell (Z): 2; unit cell volume: 1173.91 Å3; and calculated density: 1.376 g / cm3; (I). A non-solvated crystal E of the compound represented by formula (I), wherein an X-ray single-crystal diffraction pattern of the crystal is shown in FIG. 15; (I).

Images